DE69032425D1 - Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden - Google Patents

Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden

Info

Publication number: DE69032425D1
Authority: DE; Germany
Prior art keywords: nucleic acid; acid hybridization; methods; test strips; hybridization assays
Prior art date: 1990-05-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69032425T

Other languages

English (en)

Other versions

DE69032425T2 (de

Inventor

Ness Jeffrey Van

John C Tabone

Charles E Petrie

Nicolaas M J Vermeulen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nanogen Inc

Original Assignee

MicroProbe Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-11

Filing date

1990-09-04

Publication date

1998-07-23

1990-09-04 Application filed by MicroProbe Corp filed Critical MicroProbe Corp

1998-07-23 Application granted granted Critical

1998-07-23 Publication of DE69032425D1 publication Critical patent/DE69032425D1/de

1998-11-26 Publication of DE69032425T2 publication Critical patent/DE69032425T2/de

2010-09-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
238000003556 assay Methods 0.000 title abstract 2
238000007899 nucleic acid hybridization Methods 0.000 title abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
238000007654 immersion Methods 0.000 title 1
230000003100 immobilizing effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
239000011324 bead Substances 0.000 abstract 5
229920000642 polymer Polymers 0.000 abstract 4
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
239000004677 Nylon Substances 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1
229920001778 nylon Polymers 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Pathology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Saccharide Compounds (AREA)

DE69032425T 1990-05-11 1990-09-04 Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden Expired - Lifetime DE69032425T2 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US52244290A	1990-05-11	1990-05-11

Publications (2)

Publication Number	Publication Date
DE69032425D1 true DE69032425D1 (de)	1998-07-23
DE69032425T2 DE69032425T2 (de)	1998-11-26

Family

ID=24080872

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69032425T Expired - Lifetime DE69032425T2 (de)	1990-05-11	1990-09-04	Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden

Country Status (7)

Country	Link
US (1)	US5514785A (de)
EP (2)	EP0745689A3 (de)
JP (1)	JPH0420300A (de)
AT (1)	ATE167523T1 (de)
DE (1)	DE69032425T2 (de)
DK (1)	DK0455905T3 (de)
ES (1)	ES2116977T3 (de)

Families Citing this family (1021)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6040138A (en)	1995-09-15	2000-03-21	Affymetrix, Inc.	Expression monitoring by hybridization to high density oligonucleotide arrays
EP0834576B1 (de) *	1990-12-06	2002-01-16	Affymetrix, Inc. (a Delaware Corporation)	Detektion von Nukleinsäuresequenzen
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
US5747244A (en) *	1991-12-23	1998-05-05	Chiron Corporation	Nucleic acid probes immobilized on polystyrene surfaces
DE69231003T2 (de) *	1991-12-24	2000-10-19	Tepnel Medical Ltd., Manchester	Manipulation von nukleinsäuresequenzen
US6436635B1 (en)	1992-11-06	2002-08-20	Boston University	Solid phase sequencing of double-stranded nucleic acids
US5795714A (en)	1992-11-06	1998-08-18	Trustees Of Boston University	Method for replicating an array of nucleic acid probes
US6207651B1 (en) *	1996-08-02	2001-03-27	Metabolite Laboratories	Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
AU675251B2 (en) *	1993-01-04	1997-01-30	Becton Dickinson & Company	Flow-through hybridization assay for oligonucleotide sequences
US6194144B1 (en)	1993-01-07	2001-02-27	Sequenom, Inc.	DNA sequencing by mass spectrometry
US5679510A (en) *	1993-04-27	1997-10-21	Hybridon, Inc.	Quantitative detection of specific nucleic acid sequences using lambdoid bacteriophages linked by oligonucleotides to solid support
DE69433036T2 (de)	1993-09-03	2004-05-27	Isis Pharmaceuticals, Inc., Carlsbad	Aminoderivatisierte nukleoside und oligonukleoside
DE4409436A1 (de) *	1994-03-19	1995-09-21	Boehringer Mannheim Gmbh	Verfahren zur Bearbeitung von Nukleinsäuren
EP0763135B1 (de) *	1994-05-28	2002-07-10	Tepnel Medical Limited	Herstellung von nukleinsaeurekopien
US5807522A (en) *	1994-06-17	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods for fabricating microarrays of biological samples
US7378236B1 (en)	1994-06-17	2008-05-27	The Board Of Trustees Of The Leland Stanford Junior University	Method for analyzing gene expression patterns
US7323298B1 (en)	1994-06-17	2008-01-29	The Board Of Trustees Of The Leland Stanford Junior University	Microarray for determining the relative abundances of polynuceotide sequences
US5578446A (en) *	1994-07-08	1996-11-26	Becton Dickinson And Company	Analytical dipstick for improved mixing and reduced reagent volume
US8236493B2 (en) *	1994-10-21	2012-08-07	Affymetrix, Inc.	Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US6428955B1 (en)	1995-03-17	2002-08-06	Sequenom, Inc.	DNA diagnostics based on mass spectrometry
US7803529B1 (en)	1995-04-11	2010-09-28	Sequenom, Inc.	Solid phase sequencing of biopolymers
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
JP3517031B2 (ja) *	1995-06-09	2004-04-05	日清紡績株式会社	生物学的活性物質の分析法
JP2001508281A (ja) *	1995-11-14	2001-06-26	ベイラーカレッジオブメディシン	活性表面化学特性に基づく統合核酸ハイブリダイゼーション装置
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
EP0880598A4 (de)	1996-01-23	2005-02-23	Affymetrix Inc	Verfahren zur analyse von nukleinsäure
ES2288760T3 (es) *	1996-04-25	2008-01-16	Bioarray Solutions Ltd.	Ensamblaje electrocinetico controlado por luz de particulas proximas a superficies.
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US20040266706A1 (en) *	2002-11-05	2004-12-30	Muthiah Manoharan	Cross-linked oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
EP1818417B1 (de) *	1996-07-29	2014-02-12	Nanosphere, Inc.	Nanopartikel mit angehängten Oligonukleotiden und ihre Verwendungen
CA2270132A1 (en)	1996-11-06	1998-05-14	Sequenom, Inc.	Dna diagnostics based on mass spectrometry
JP2008298785A (ja) *	1996-11-06	2008-12-11	Sequenom Inc	固体支持体に核酸を固定化するための組成物および方法
US6133436A (en)	1996-11-06	2000-10-17	Sequenom, Inc.	Beads bound to a solid support and to nucleic acids
DE19782097T1 (de) *	1996-11-06	1999-10-14	Sequenom Inc	Zusammensetzungen und Verfahren zur Immobilisierung von Nucleinsäuren an feste Träger
US5900481A (en) *	1996-11-06	1999-05-04	Sequenom, Inc.	Bead linkers for immobilizing nucleic acids to solid supports
EP1457496B1 (de)	1996-11-06	2014-01-15	Sequenom, Inc.	Immobilisierung mit hoher Dichte von Nukleinsäuren
AU2002300406B9 (en) *	1996-11-06	2005-11-03	Sequenom, Inc.	Compositions and Methods for Immobilizing Nucleic Acids to Solid Supports
US6140053A (en)	1996-11-06	2000-10-31	Sequenom, Inc.	DNA sequencing by mass spectrometry via exonuclease degradation
EP1003908B1 (de) *	1997-04-16	2006-12-06	Applera Corporation	Nukleinsäuresammlung
EP1012331B1 (de)	1997-07-01	2006-03-29	Isis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
CN1264319A (zh)	1997-07-22	2000-08-23	拉普吉恩公司	用于将溶液排列到固体支持物上的装置和方法
US6268131B1 (en)	1997-12-15	2001-07-31	Sequenom, Inc.	Mass spectrometric methods for sequencing nucleic acids
WO1999042620A2 (en) *	1998-02-19	1999-08-26	Edvotek	Articles of manufacture and methods for staining biomolecules
US6013789A (en) *	1998-02-20	2000-01-11	Beckman Coulter, Inc.	Covalent attachment of biomolecules to derivatized polypropylene supports
EP1058832A1 (de) *	1998-02-21	2000-12-13	Basf Aktiengesellschaft	Verwendung von fluoreszenzfarbstoffen zur oberflächenuntersuchung
US7321828B2 (en)	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
US20040186071A1 (en) *	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US6048695A (en) *	1998-05-04	2000-04-11	Baylor College Of Medicine	Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6979728B2 (en) *	1998-05-04	2005-12-27	Baylor College Of Medicine	Articles of manufacture and methods for array based analysis of biological molecules
US6723564B2 (en)	1998-05-07	2004-04-20	Sequenom, Inc.	IR MALDI mass spectrometry of nucleic acids using liquid matrices
AU745880B2 (en) *	1998-05-21	2002-04-11	Isis Pharmaceuticals, Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
CA2329252A1 (en) *	1998-05-21	1999-11-25	Isis Pharmaceuticals Inc.	Compositions and methods for topical delivery of oligonucleotides
US6335439B1 (en)	1998-06-11	2002-01-01	Isis Pharmaceuticals, Inc.	Method of preparing phosphoramidites
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6667176B1 (en)	2000-01-11	2003-12-23	Geron Corporation	cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
BE1012275A3 (fr) *	1998-11-12	2000-08-01	Univ Bruxelles	Fixation covalente d'oligonucleotides a la surface du nylon.
US6919200B2 (en) *	1998-11-23	2005-07-19	The United States Of America As Represented By The Secretary Of The Army	Purification method and apparatus
US6638760B1 (en) *	1998-11-25	2003-10-28	Pe Corporation (Ny)	Method and apparatus for flow-through hybridization
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
DE19903576C2 (de)	1999-01-29	2001-02-22	Bodenseewerk Perkin Elmer Co	Quantitative Bestimmung von Analyten in einem heterogenen System
DE60030957T2 (de)	1999-02-16	2007-06-14	Applera Corp., Foster City	Kugelabgabesystem
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6268141B1 (en) *	1999-05-12	2001-07-31	Beckman Coulter, Inc.	Immobilization of unmodified biopolymers to acyl fluoride activated substrates
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6339147B1 (en)	1999-07-29	2002-01-15	Epoch Biosciences, Inc.	Attachment of oligonucleotides to solid supports through Schiff base type linkages for capture and detection of nucleic acids
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6617442B1 (en)	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
US20030190644A1 (en) *	1999-10-13	2003-10-09	Andreas Braun	Methods for generating databases and databases for identifying polymorphic genetic markers
JP2003517589A (ja) *	1999-11-02	2003-05-27	セリーヌフー，	分子マイクロアレイならびにその生産および使用のための方法
US7109024B2 (en) *	1999-11-15	2006-09-19	Dr. Chip Biotechnology Inc.	Biomolecule-bound substrates
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
WO2001058561A1 (en) *	2000-02-09	2001-08-16	Resq Lab B.V.	Packing materials for separation of biomolecules
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
US6413722B1 (en)	2000-03-22	2002-07-02	Incyte Genomics, Inc.	Polymer coated surfaces for microarray applications
US6911535B2 (en) *	2000-03-22	2005-06-28	Solvlink Biosciences	Biomolecule/polymer conjugates
DE60140864D1 (de) *	2000-04-13	2010-02-04	Thomas N Wight	Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican
US6458589B1 (en)	2000-04-27	2002-10-01	Geron Corporation	Hepatocyte lineage cells derived from pluripotent stem cells
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
EP1356088A2 (de) *	2000-06-07	2003-10-29	Baylor College of Medicine	Zusammensetzungen und methoden zur array-gestützten nukleinsäurehybridisierung
US20060166227A1 (en) *	2000-06-20	2006-07-27	Stephen Kingsmore	Protein expression profiling
US9709559B2 (en)	2000-06-21	2017-07-18	Bioarray Solutions, Ltd.	Multianalyte molecular analysis using application-specific random particle arrays
AU2001272993B2 (en)	2000-06-21	2005-03-10	Bioarray Solutions, Ltd.	Multianalyte molecular analysis
US6323009B1 (en) *	2000-06-28	2001-11-27	Molecular Staging, Inc.	Multiply-primed amplification of nucleic acid sequences
US6958214B2 (en)	2000-07-10	2005-10-25	Sequenom, Inc.	Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2001296846B2 (en)	2000-10-12	2007-07-05	University Of Rochester	Compositions that inhibit proliferation of cancer cells
US20030045005A1 (en) *	2000-10-17	2003-03-06	Michael Seul	Light-controlled electrokinetic assembly of particles near surfaces
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2002061146A1 (en) *	2001-02-01	2002-08-08	The Trustees Of Columbia University In The City Of New York	Use of electrical fields to control interactions between proteins and nucleic acid constructions immobilized on solid supports
DE60232785D1 (de)	2001-03-14	2009-08-13	Myriad Genetics Inc	Tsg101-gag-wechselwirkung und ihre verwendung
EP1992643A3 (de)	2001-06-20	2008-12-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7262063B2 (en)	2001-06-21	2007-08-28	Bio Array Solutions, Ltd.	Directed assembly of functional heterostructures
CA2451643C (en)	2001-06-21	2012-11-13	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US7687437B2 (en)	2001-07-13	2010-03-30	Nanosphere, Inc.	Method for immobilizing molecules onto surfaces
CA2563510A1 (en)	2001-07-13	2005-11-17	Nanosphere, Inc.	Method for preparing substrates having immobilized molecules and substrates
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
EP2143438B1 (de)	2001-09-18	2011-07-13	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US7195913B2 (en)	2001-10-05	2007-03-27	Surmodics, Inc.	Randomly ordered arrays and methods of making and using
ATE295155T1 (de)	2001-10-05	2005-05-15	Surmodics Inc	Beschichtungen mit immobilisierten partikeln sowie verwendungen derselben
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2002334895B2 (en)	2001-10-09	2006-10-19	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2002367886B8 (en) *	2001-10-12	2008-08-14	Perkinelmer Las, Inc.	Compilations of nucleic acids and arrays and methods of using them
US7439346B2 (en) *	2001-10-12	2008-10-21	Perkinelmer Las Inc.	Nucleic acids arrays and methods of use therefor
KR20040068122A (ko)	2001-10-15	2004-07-30	바이오어레이 솔루션스 리미티드	공동 검색과 효소-매개된 탐지에 의한 다형성 좌위의 다중분석
US20030224380A1 (en) *	2001-10-25	2003-12-04	The General Hospital Corporation	Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
AU2002364945A1 (en) *	2001-10-25	2003-07-09	Neurogenetics, Inc.	Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
US20030170678A1 (en) *	2001-10-25	2003-09-11	Neurogenetics, Inc.	Genetic markers for Alzheimer's disease and methods using the same
DE10154291B4 (de) *	2001-11-05	2005-05-19	Hain Lifescience Gmbh	Verfahren zum Nachweis von Nukleinsäuren in Form eines Trockenschnelltestes
WO2003042697A1 (en) *	2001-11-14	2003-05-22	Genospectra, Inc.	Biochemical analysis system with combinatorial chemistry applications
US6927029B2 (en)	2001-12-03	2005-08-09	Agilent Technologies, Inc.	Surface with tethered polymeric species for binding biomolecules
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
US20030119203A1 (en)	2001-12-24	2003-06-26	Kimberly-Clark Worldwide, Inc.	Lateral flow assay devices and methods for conducting assays
US8367013B2 (en) *	2001-12-24	2013-02-05	Kimberly-Clark Worldwide, Inc.	Reading device, method, and system for conducting lateral flow assays
JP3634307B2 (ja) *	2001-12-27	2005-03-30	三菱電機株式会社	チャット管理システム
US20030124542A1 (en) *	2001-12-28	2003-07-03	Spectral Genomics, Inc.	Methods for mapping the chromosomal loci of genes expressed by a cell
NZ533933A (en)	2002-01-02	2008-06-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of glioma tumor
US7122314B2 (en) *	2002-01-30	2006-10-17	Id Biomedical Corporation	Methods for detecting vancomycin-resistant microorganisms and compositions therefor
CA2474530A1 (en) *	2002-02-07	2003-08-14	Eastern Virginia Medical School Of The Medical College Of Hampton Roads	Diagnostic microarray and method of use thereof
US7553619B2 (en) *	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
AU2003228348A1 (en) *	2002-03-20	2003-10-08	John T. Fassett	Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
KR20040101502A (ko)	2002-04-16	2004-12-02	제넨테크, 인크.	종양의 진단 및 치료 방법 및 이를 위한 조성물
AU2003228809A1 (en) *	2002-05-03	2003-11-17	Sequenom, Inc.	Kinase anchor protein muteins, peptides thereof, and related methods
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
AU2003276131A1 (en) *	2002-06-18	2003-12-31	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
JP2004097173A (ja) *	2002-07-17	2004-04-02	Toyo Kohan Co Ltd	静電層を有する固体支持体及びその用途
US20040019000A1 (en) *	2002-07-19	2004-01-29	Muthiah Manoharan	Polyalkyleneamine-containing oligomers
CA2495478A1 (en)	2002-08-05	2004-02-12	University Of Rochester	Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US6878805B2 (en) *	2002-08-16	2005-04-12	Isis Pharmaceuticals, Inc.	Peptide-conjugated oligomeric compounds
US7508608B2 (en)	2004-11-17	2009-03-24	Illumina, Inc.	Lithographically fabricated holographic optical identification element
EP1535241A1 (de) *	2002-08-20	2005-06-01	Cyvera Corporation	Auf einem beugungsgitter basierendes optisches identifikationselement
US7872804B2 (en)	2002-08-20	2011-01-18	Illumina, Inc.	Encoded particle having a grating with variations in the refractive index
US7164533B2 (en)	2003-01-22	2007-01-16	Cyvera Corporation	Hybrid random bead/chip based microarray
US7900836B2 (en)	2002-08-20	2011-03-08	Illumina, Inc.	Optical reader system for substrates having an optically readable code
US7441703B2 (en)	2002-08-20	2008-10-28	Illumina, Inc.	Optical reader for diffraction grating-based encoded optical identification elements
US7901630B2 (en)	2002-08-20	2011-03-08	Illumina, Inc.	Diffraction grating-based encoded microparticle assay stick
US7399643B2 (en) *	2002-09-12	2008-07-15	Cyvera Corporation	Method and apparatus for aligning microbeads in order to interrogate the same
US7619819B2 (en)	2002-08-20	2009-11-17	Illumina, Inc.	Method and apparatus for drug product tracking using encoded optical identification elements
EP2261868A2 (de) *	2002-08-20	2010-12-15	Cyvera Corporation	Auf Beugungsgittern Basiertes Optisches Identifizierungselement und seine Anwendungen
US7923260B2 (en)	2002-08-20	2011-04-12	Illumina, Inc.	Method of reading encoded particles
US7432105B2 (en)	2002-08-27	2008-10-07	Kimberly-Clark Worldwide, Inc.	Self-calibration system for a magnetic binding assay
US7285424B2 (en) *	2002-08-27	2007-10-23	Kimberly-Clark Worldwide, Inc.	Membrane-based assay devices
US7314763B2 (en) *	2002-08-27	2008-01-01	Kimberly-Clark Worldwide, Inc.	Fluidics-based assay devices
EP1540590A1 (de) *	2002-09-12	2005-06-15	Cyvera Corporation	Kodierte mikrokugeln enthaltendes versuchsstäbchen
US7092160B2 (en)	2002-09-12	2006-08-15	Illumina, Inc.	Method of manufacturing of diffraction grating-based optical identification element
AU2003278827A1 (en) *	2002-09-12	2004-04-30	Cyvera Corp.	Method and apparatus for labelling using diffraction grating-based encoded optical identification elements
US20100255603A9 (en)	2002-09-12	2010-10-07	Putnam Martin A	Method and apparatus for aligning microbeads in order to interrogate the same
CA2498916A1 (en) *	2002-09-12	2004-03-25	Cyvera Corporation	Chemical synthesis using diffraction grating-based encoded optical elements
AU2003270726A1 (en) *	2002-09-12	2004-04-30	Cidra Corporation	Diffraction grating-based encoded micro-particles for multiplexed experiments
AU2003267785C1 (en)	2002-09-13	2009-12-24	Replicor, Inc.	Non-sequence complementary antiviral oligonucleotides
JP2006500030A (ja) *	2002-09-20	2006-01-05	イェールユニバーシティ	リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
AU2003275018B2 (en) *	2002-09-20	2009-10-01	Integrated Dna Technologies, Inc.	Anthraquinone quencher dyes, their methods of preparation and use
EP1549767A4 (de)	2002-09-26	2006-06-07	Amgen Inc	Modulation der expression von forkhead-box o1a
JP2006515318A (ja) *	2002-10-29	2006-05-25	ファルマシア・コーポレーション	特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP1562971B1 (de)	2002-11-05	2014-02-12	Isis Pharmaceuticals, Inc.	Polyzyklischen zuckerersatz beinhaltende oligomere verbindungen und zusammensetzungen zur verwendung bei der genmodulation
AU2003295387A1 (en)	2002-11-05	2004-06-03	Isis Parmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004044138A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
PT2336318E (pt)	2002-11-13	2013-06-12	Genzyme Corp	Modulação anti-sentido da expressão de apolipoproteína b
JP4986109B2 (ja)	2002-11-13	2012-07-25	ジェンザイム・コーポレーション	アポリポタンパク質ｂ発現のアンチセンス調節
AU2003298655A1 (en)	2002-11-15	2004-06-15	Bioarray Solutions, Ltd.	Analysis, secure access to, and transmission of array images
CA2505601C (en)	2002-11-15	2014-10-28	Musc Foundation For Research Development	Complement receptor 2 targeted complement modulators
DE60329526D1 (de) *	2002-11-15	2009-11-12	Morphotek Inc	Verfahren zur erzeugung einer hohen antikörperproduktion von durch in-vitro-immunisierung entstandenen hybridomen
WO2004047749A2 (en)	2002-11-21	2004-06-10	University Of Utah Research Foundation	Purinergic modulation of smell
US7781172B2 (en) *	2003-11-21	2010-08-24	Kimberly-Clark Worldwide, Inc.	Method for extending the dynamic detection range of assay devices
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US20040121334A1 (en) *	2002-12-19	2004-06-24	Kimberly-Clark Worldwide, Inc.	Self-calibrated flow-through assay devices
US7247500B2 (en) *	2002-12-19	2007-07-24	Kimberly-Clark Worldwide, Inc.	Reduction of the hook effect in membrane-based assay devices
US20040121339A1 (en) *	2002-12-19	2004-06-24	Jizhong Zhou	Special film-coated substrate for bio-microarray fabrication and use thereof
AU2003299694A1 (en)	2002-12-20	2004-07-22	Qiagen Gmbh	Nucleic acid amplification
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
NZ541637A (en)	2003-02-11	2008-07-31	Antisense Therapeutics Pty Ltd	Modulation of insulin like growth factor I receptor
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20070141570A1 (en) *	2003-03-07	2007-06-21	Sequenom, Inc.	Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US7851209B2 (en) *	2003-04-03	2010-12-14	Kimberly-Clark Worldwide, Inc.	Reduction of the hook effect in assay devices
US20040197819A1 (en) *	2003-04-03	2004-10-07	Kimberly-Clark Worldwide, Inc.	Assay devices that utilize hollow particles
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
EP1660512A4 (de) *	2003-06-02	2009-12-23	Isis Pharmaceuticals Inc	Oligonucleotid-synthese mit alternativen lösungsmitteln
BRPI0410886A (pt)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
EP1633770B1 (de)	2003-06-13	2015-04-29	Alnylam Europe AG	Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus
WO2004113496A2 (en) *	2003-06-20	2004-12-29	Isis Pharmaceuticals, Inc.	Double stranded compositions comprising a 3’-endo modified strand for use in gene modulation
WO2005013901A2 (en)	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) *	2003-09-11	2007-05-31	Replicor Inc.	Oligonucleotides targeting prion diseases
WO2005029705A2 (en)	2003-09-18	2005-03-31	Bioarray Solutions, Ltd.	Number coding for identification of subtypes of coded types of solid phase carriers
NZ545134A (en)	2003-09-18	2009-06-26	Lilly Co Eli	Modulation of eIF4E expression
AU2004274021B2 (en) *	2003-09-18	2009-08-13	Isis Pharmaceuticals, Inc.	4'-thionucleosides and oligomeric compounds
US7595279B2 (en)	2003-09-22	2009-09-29	Bioarray Solutions Ltd.	Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
US7662929B2 (en)	2003-10-10	2010-02-16	Alchemia Oncology Pty Limited	Antibody that specifically binds hyaluronan synthase
EP1692298A4 (de)	2003-10-28	2008-08-13	Bioarray Solutions Ltd	Optimierung der genexpressionsanalyse unter verwendung immobilisierter fängersonden
NZ547495A (en)	2003-10-29	2008-05-30	Bioarray Solutions Ltd	Multiplexed nucleic acid analysis by fragmentation of double-stranded DNA
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
US7439341B2 (en)	2003-11-14	2008-10-21	Integrated Dna Technologies, Inc.	Fluorescence quenching azo dyes, their methods of preparation and use
NZ596984A (en)	2003-11-17	2013-10-25	Genentech Inc	Compositions and methods for the treatment of tumor of hematopoietic origin
US7943395B2 (en) *	2003-11-21	2011-05-17	Kimberly-Clark Worldwide, Inc.	Extension of the dynamic detection range of assay devices
US7713748B2 (en) *	2003-11-21	2010-05-11	Kimberly-Clark Worldwide, Inc.	Method of reducing the sensitivity of assay devices
US20050112703A1 (en)	2003-11-21	2005-05-26	Kimberly-Clark Worldwide, Inc.	Membrane-based lateral flow assay devices that utilize phosphorescent detection
US7943089B2 (en) *	2003-12-19	2011-05-17	Kimberly-Clark Worldwide, Inc.	Laminated assay devices
US20050136500A1 (en) *	2003-12-19	2005-06-23	Kimberly-Clark Worldwide; Inc.	Flow-through assay devices
US20050136550A1 (en) *	2003-12-19	2005-06-23	Kimberly-Clark Worldwide, Inc.	Flow control of electrochemical-based assay devices
US20050164271A1 (en)	2004-01-20	2005-07-28	Sanjay Bhanot	Modulation of glucocorticoid receptor expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US7433123B2 (en)	2004-02-19	2008-10-07	Illumina, Inc.	Optical identification element having non-waveguide photosensitive substrate with diffraction grating therein
US20050191704A1 (en) *	2004-03-01	2005-09-01	Kimberly-Clark Worldwide, Inc.	Assay devices utilizing chemichromic dyes
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP2700720A3 (de)	2004-03-15	2015-01-28	Isis Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
US20050260652A1 (en) *	2004-04-15	2005-11-24	The General Hospital Corporation	Compositions and methods that modulate RNA interference
EP3034510A1 (de)	2004-04-30	2016-06-22	Alnylam Pharmaceuticals Inc.	Oligonukleotide mit c5-modifiziertem pyrimidin
JP2008500064A (ja)	2004-05-21	2008-01-10	ザユーエービーリサーチファウンデーション	可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用
EP1766052A4 (de) *	2004-06-03	2009-12-16	Isis Pharmaceuticals Inc	Chimärische oligomere zusammensetzungen mit gap
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
CA2569419A1 (en) *	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US7521226B2 (en)	2004-06-30	2009-04-21	Kimberly-Clark Worldwide, Inc.	One-step enzymatic and amine detection technique
US7094528B2 (en) *	2004-06-30	2006-08-22	Kimberly-Clark Worldwide, Inc.	Magnetic enzyme detection techniques
US7906276B2 (en) *	2004-06-30	2011-03-15	Kimberly-Clark Worldwide, Inc.	Enzymatic detection techniques
US7848889B2 (en)	2004-08-02	2010-12-07	Bioarray Solutions, Ltd.	Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
US7427675B2 (en) *	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
PL1809303T3 (pl)	2004-09-23	2019-11-29	Arc Medical Devices Inc	Kompozycje farmaceutyczne i sposoby dotyczące hamowania zrostów włóknistych lub stanów zapalnych przy użyciu fukanów o niskiej zawartości siarczanów
AU2005327506B2 (en)	2004-10-20	2010-07-08	Antisense Therapeutics Ltd	Antisense modulation of integrin alpha4 expression
US7604173B2 (en)	2004-11-16	2009-10-20	Illumina, Inc.	Holographically encoded elements for microarray and other tagging labeling applications, and method and apparatus for making and reading the same
WO2006055735A2 (en)	2004-11-16	2006-05-26	Illumina, Inc	Scanner having spatial light modulator
WO2006055736A1 (en)	2004-11-16	2006-05-26	Illumina, Inc.	And methods and apparatus for reading coded microbeads
US20100256062A1 (en) *	2004-12-06	2010-10-07	Howard Tommy E	Allelic Variants of Human Factor VIII
US20060281680A1 (en)	2005-03-10	2006-12-14	Genentech, Inc.	Methods and compositions for modulating vascular integrity
US7476733B2 (en) *	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en)	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
US20060281076A1 (en) *	2005-05-18	2006-12-14	Nanosphere, Inc.	Substrate functionalization method for high sensitivity applications
WO2006127507A2 (en) *	2005-05-20	2006-11-30	Integrated Dna Technologies, Inc.	Compounds and methods for labeling oligonucleotides
WO2007008300A2 (en)	2005-05-31	2007-01-18	ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE	Triblock copolymers for cytoplasmic delivery of gene-based drugs
US8486629B2 (en)	2005-06-01	2013-07-16	Bioarray Solutions, Ltd.	Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation
WO2006133022A2 (en)	2005-06-03	2006-12-14	The Johns Hopkins University	Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US8252756B2 (en)	2005-06-14	2012-08-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
CA2618665C (en)	2005-08-11	2012-11-13	J. Craig Venter Institute	Method for in vitro recombination
US20100015604A1 (en)	2005-08-17	2010-01-21	Evriklia Lianidou	Composition and method for determination of ck19 expression
JP5523705B2 (ja)	2005-08-29	2014-06-18	レグルス・セラピューティクス・インコーポレイテッド	Ｍｉｒ−１２２ａをモジュレートする使用方法
US20090203893A1 (en)	2005-08-29	2009-08-13	Regulus Therapeutics, Llc	Antisense compounds having enhanced anti-microrna activity
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2392646A1 (de)	2005-10-14	2011-12-07	MUSC Foundation For Research Development	Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
CN101365801B (zh) *	2005-10-28	2013-03-27	阿尔尼拉姆医药品有限公司	抑制亨廷顿基因表达的组合物和方法
JP4929288B2 (ja) *	2005-11-04	2012-05-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｎａｖ１．８遺伝子の発現を抑制するための組成物および方法
CA2626690A1 (en)	2005-11-09	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
CA2630602A1 (en)	2005-11-21	2007-05-31	Isis Pharmaceuticals, Inc.	Modulation of eif4e-bp2 expression
US7623624B2 (en)	2005-11-22	2009-11-24	Illumina, Inc.	Method and apparatus for labeling using optical identification elements characterized by X-ray diffraction
EP1974052A2 (de) *	2005-12-21	2008-10-01	Yale University	Verfahren und zusammensetzungen in verbindung mit der modulation von riboschaltern
CN103301475B (zh)	2005-12-28	2016-08-03	斯克里普斯研究所	药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
JP5425474B2 (ja)	2006-01-26	2014-02-26	アイシスファーマシューティカルズ，インコーポレーテッド	ハンチンチン対する、組成物及びその使用
CA2640171C (en)	2006-01-27	2014-10-28	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
JP5213723B2 (ja)	2006-01-27	2013-06-19	アイシスファーマシューティカルズ，インコーポレーテッド	マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
US20090305262A1 (en) *	2006-03-31	2009-12-10	Canon Kabushiki Kaisha	Probe, probe set, probe-immobilized carrier, and genetic testing method
JP5704741B2 (ja)	2006-03-31	2015-04-22	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｅｇ５遺伝子発現の抑制のための組成物および方法
US7830575B2 (en)	2006-04-10	2010-11-09	Illumina, Inc.	Optical scanner with improved scan time
US20070258862A1 (en) *	2006-05-02	2007-11-08	Applera Corporation	Variable volume dispenser and method
JP2009535383A (ja) *	2006-05-03	2009-10-01	バルティックテクロノジーデヴェロプメント，リミテッド	強く結合した塩基で修飾されたオリゴヌクレオチドと人工ヌクレアーゼを組み合わせたアンチセンス作用物質
EP2505649A1 (de)	2006-05-05	2012-10-03	Isis Pharmaceuticals, Inc.	Verbindungen und Verfahren zur Modulation der Expression von GCGR
CA3044969A1 (en) *	2006-05-05	2007-12-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating gene expression
JP5441688B2 (ja) *	2006-05-11	2014-03-12	アイシスファーマシューティカルズ，インコーポレーテッド	５’修飾二環式核酸類似体
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
JP2009537153A (ja)	2006-05-19	2009-10-29	アルニラムファーマシューティカルズ，インコーポレイテッド	ＡｈａのＲＮＡｉ調節およびその治療上の使用
AU2007253677B2 (en)	2006-05-22	2011-02-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of IKK-B gene
EP2023938A4 (de) *	2006-05-23	2010-11-10	Isis Pharmaceuticals Inc	Modulation von chrebp-expression
US9506056B2 (en) *	2006-06-08	2016-11-29	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
US20090280188A1 (en) *	2006-06-23	2009-11-12	Northwestern University	Asymmetric functionalizated nanoparticles and methods of use
WO2008011473A2 (en)	2006-07-19	2008-01-24	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to hbxip
US8101585B2 (en) *	2006-08-04	2012-01-24	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of JNK proteins
US20090047673A1 (en)	2006-08-22	2009-02-19	Cary Robert B	Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
EP2061799A4 (de) *	2006-09-11	2010-12-22	Univ Yale	Verfahren und zusammensetzungen zur verwendung von lysin-riboswitches
CA2665536C (en)	2006-10-05	2016-02-16	Massachusetts Institute Of Technology	Multifunctional encoded particles for high-throughput analysis
DK2092065T4 (da) *	2006-10-18	2019-10-21	Ionis Pharmaceuticals Inc	Antisense-forbindelser
EP2104516B1 (de)	2006-11-01	2015-01-07	University of Rochester	Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
EP2453016A1 (de) *	2006-11-27	2012-05-16	Isis Pharmaceuticals, Inc.	Verfahren zur Behandlung von Hypercholesterinämie
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
CN101600451A (zh)	2006-12-11	2009-12-09	犹他大学研究基金会	用于治疗病理性血管生成和血管通透性的组合物和方法
US20100129358A1 (en)	2006-12-22	2010-05-27	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
CA2691066C (en) *	2007-02-09	2018-07-31	Northwestern University	Particles for detecting intracellular targets
AU2008239495A1 (en) *	2007-02-27	2008-10-23	Northwestern University	Molecule attachment to nanoparticles
MX2009010081A (es)	2007-03-22	2010-01-20	Univ Yale	Metodos y composiciones relacionadas con los ribointerruptores (riboswitches) que controlan el corte y empalme (splicing) alternativo.
AP3018A (en)	2007-03-29	2014-10-31	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expressionof a gene from the ebola
WO2008141275A1 (en)	2007-05-11	2008-11-20	The Johns Hopkins University	Biomarkers for melanoma
US20100221821A1 (en) *	2007-05-29	2010-09-02	Yale University	Methods and compositions related to riboswitches that control alternative splicing and rna processing
SG174103A1 (en)	2007-05-29	2011-09-29	Univ Yale	Riboswitches and methods and compositions for use of and with riboswitches
EP2170917B1 (de)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
US7807372B2 (en) *	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
ES2386492T3 (es)	2007-06-08	2012-08-21	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos carbocíclicos
CN101796062B (zh) *	2007-07-05	2014-07-30	Isis制药公司	6-双取代双环核酸类似物
JP5572090B2 (ja)	2007-08-15	2014-08-13	アイシスファーマシューティカルズ，インコーポレーテッド	テトラヒドロピラン核酸類似体
AU2008296478B9 (en)	2007-08-28	2015-03-19	The Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8557767B2 (en)	2007-08-28	2013-10-15	Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8445217B2 (en)	2007-09-20	2013-05-21	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en) *	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
AU2008307482B2 (en)	2007-10-02	2012-07-12	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-RNA and precursors thereof
CA2704560A1 (en) *	2007-11-05	2009-05-14	Baltic Technology Development, Ltd.	Use of oligonucleotides with modified bases in hybridization of nucleic acids
US8916531B2 (en) *	2007-11-20	2014-12-23	Isis Pharmaceuticals, Inc.	Modulation of CD40 expression
EP2617828B1 (de)	2007-12-10	2014-09-24	Alnylam Pharmaceuticals Inc.	Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
EP2224912B1 (de)	2008-01-02	2016-05-11	TEKMIRA Pharmaceuticals Corporation	Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
EP2265627A2 (de) *	2008-02-07	2010-12-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexitolnukleinsäureanaloga
US20090215050A1 (en) *	2008-02-22	2009-08-27	Robert Delmar Jenison	Systems and methods for point-of-care amplification and detection of polynucleotides
MX2010009611A (es)	2008-03-05	2010-12-15	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion de genes eg5 y vegf.
US8426378B2 (en)	2008-03-21	2013-04-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucelosides and methods for their use
EP2105145A1 (de) *	2008-03-27	2009-09-30	ETH Zürich	Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
WO2009124238A1 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
EP2274423A2 (de) *	2008-04-04	2011-01-19	Isis Pharmaceuticals, Inc.	Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
WO2009126933A2 (en)	2008-04-11	2009-10-15	Alnylam Pharmaceuticals, Inc.	Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
ES2686708T3 (es)	2008-04-18	2018-10-19	Baxter International Inc.	Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
US8324366B2 (en)	2008-04-29	2012-12-04	Alnylam Pharmaceuticals, Inc.	Compositions and methods for delivering RNAI using lipoproteins
WO2009134917A2 (en) *	2008-04-29	2009-11-05	Wyeth	Methods for treating inflammation
WO2009137059A1 (en)	2008-05-05	2009-11-12	Los Alamos National Security, Llc	Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control
CA2726052A1 (en)	2008-06-04	2009-12-10	The Board Of Regents Of The University Of Texas System	Modulation of gene expression through endogenous small rna targeting of gene promoters
JP2011529686A (ja)	2008-07-29	2011-12-15	ザボードオブリージェンツオブザユニバーシティーオブテキサスシステム	ポリグルタミンタンパク質発現の選択的阻害
US20110237646A1 (en) *	2008-08-07	2011-09-29	Isis Pharmaceuticals, Inc.	Modulation of transthyretin expression for the treatment of cns related disorders
DK2331141T3 (en)	2008-08-25	2016-04-04	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
ES2657696T3 (es)	2008-08-25	2018-03-06	Excaliard Pharmaceuticals, Inc.	Método para reducir la cicatrización durante la curación de una herida utilizando compuestos antisentido dirigidos al CTGF
US8318693B2 (en)	2008-09-02	2012-11-27	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mutant EGFR gene
EP3587434A1 (de)	2008-09-23	2020-01-01	Alnylam Pharmaceuticals Inc.	Chemische modifikationen von monomeren und oligonukleotiden mit click komponenten um liganden zu konjugieren
DK2356129T3 (da) *	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
DK2361256T3 (da)	2008-09-24	2013-07-01	Isis Pharmaceuticals Inc	Cyclohexenyl-nukleinsyreanaloger
EP2334793B1 (de)	2008-09-25	2016-04-06	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
JP5777519B2 (ja)	2008-10-09	2015-09-09	テクミラファーマシューティカルズコーポレイション	改良されたアミノ脂質および核酸の送達方法
HRP20171969T1 (hr)	2008-10-15	2018-04-06	Ionis Pharmaceuticals, Inc.	Modulacija ekspresije faktora 11
SG10201809460SA (en)	2008-10-20	2018-11-29	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of transthyretin
AU2009308217B2 (en)	2008-10-24	2016-01-21	Ionis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
US8987435B2 (en)	2008-10-24	2015-03-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
DK2355851T3 (en)	2008-11-10	2018-06-25	Arbutus Biopharma Corp	Newly known lipids and compositions for release of therapeutic agents
CN102281872A (zh)	2008-11-24	2011-12-14	西北大学	多价rna纳米颗粒组合物
KR101829469B1 (ko)	2008-12-04	2018-03-30	큐알엔에이, 인크.	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
CN108042560A (zh)	2008-12-04	2018-05-18	库尔纳公司	通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病
KR101866152B1 (ko)	2008-12-04	2018-06-08	큐알엔에이, 인크.	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CA2746514C (en)	2008-12-10	2018-11-27	Alnylam Pharmaceuticals, Inc.	Gnaq targeted dsrna compositions and methods for inhibiting expression
CA2749536A1 (en) *	2009-01-08	2010-07-15	Northwestern University	Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
US20120101148A1 (en)	2009-01-29	2012-04-26	Alnylam Pharmaceuticals, Inc.	lipid formulation
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
KR101682735B1 (ko)	2009-02-12	2016-12-06	큐알엔에이, 인크.	뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료
ES2658626T3 (es)	2009-02-12	2018-03-12	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
WO2010101951A1 (en)	2009-03-02	2010-09-10	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
EP2403946A4 (de)	2009-03-04	2012-11-14		Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
NZ594995A (en)	2009-03-12	2013-06-28	Alnylam Pharmaceuticals Inc	LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
MX2011009751A (es)	2009-03-16	2011-09-29	Opko Curna Llc	Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
JP5904935B2 (ja)	2009-03-17	2016-04-20	クルナ・インコーポレーテッド	デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
CN102449170A (zh)	2009-04-15	2012-05-09	西北大学	寡核苷酸功能化的纳米颗粒的递送
EP3524275A1 (de)	2009-04-22	2019-08-14	Massachusetts Institute Of Technology	Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
WO2010124231A2 (en)	2009-04-24	2010-10-28	The Board Of Regents Of The University Of Texas System	Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
CA2760589C (en)	2009-05-01	2019-08-20	Joseph Collard	Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
CA2760776C (en)	2009-05-05	2019-07-09	Alnylam Pharmaceuticals, Inc.	Lipid compositions for the delivery of therapeutic agents
CA3045126A1 (en)	2009-05-05	2010-11-11	Arbutus Biopharma Corporation	Methods of delivering oligonucleotides to immune cells
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
JP6250930B2 (ja)	2009-05-06	2017-12-20	クルナ・インコーポレーテッド	トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
US20120107331A1 (en)	2009-05-15	2012-05-03	Yale University	Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
JP5922017B2 (ja)	2009-05-18	2016-05-24	クルナ・インコーポレーテッド	リプログラミング因子に対する天然アンチセンス転写物の抑制によるリプログラミング因子関連疾患の治療
EP2432882B1 (de)	2009-05-22	2019-12-25	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
WO2010138806A2 (en)	2009-05-28	2010-12-02	Curna, Inc.	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CA2764609C (en)	2009-06-10	2018-10-02	Alnylam Pharmaceuticals, Inc.	Improved cationic lipid of formula i
JP5944311B2 (ja)	2009-06-16	2016-07-05	クルナ・インコーポレーテッド	コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
JP6128846B2 (ja)	2009-06-16	2017-05-17	クルナ・インコーポレーテッド	パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
PT3449926T (pt)	2009-06-17	2019-11-12	Cold Spring Harbor Laboratory	Composições e métodos de modulação de excisões de smn2 em um sujeito
EP2446036B1 (de)	2009-06-24	2017-03-01	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit tumornekrose faktor-rezeptor 2 (tnfr2) mittels hemmung des natürlichen antisense-transkripts gegen tnfr2
US8921330B2 (en)	2009-06-26	2014-12-30	Curna, Inc.	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
ES2585360T3 (es)	2009-08-05	2016-10-05	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
WO2011017521A2 (en)	2009-08-06	2011-02-10	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
AP2015008874A0 (en)	2009-08-14	2015-11-30	Alnylam Pharmaceuticals Inc	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en)	2009-08-17	2012-06-21	Yale University	Methylation biomarkers and methods of use
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
EP2473522B1 (de)	2009-09-02	2016-08-17	Genentech, Inc.	Smoothened-mutant und verfahren zu seiner anwendung
CA2778442A1 (en)	2009-10-22	2011-04-28	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
JP6147502B2 (ja)	2009-10-27	2017-06-14	スウィフトバイオサイエンシーズ，インコーポレイテッド	ポリヌクレオチドプライマー及びプローブ
KR20120136345A (ko)	2009-10-30	2012-12-18	노오쓰웨스턴 유니버시티	주형화된 나노컨쥬게이트
WO2011053994A1 (en)	2009-11-02	2011-05-05	Alnylam Pharmaceuticals, Inc.	Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
AU2010315867A1 (en)	2009-11-03	2012-06-21	University Of Virginia Patent Foundation	Versatile, visible method for detecting polymeric analytes
WO2011063403A1 (en)	2009-11-23	2011-05-26	Swift Biosciences, Inc.	Devices to extend single stranded target molecules
TWI537383B (zh)	2009-11-30	2016-06-11	建南德克公司	診斷及治療腫瘤之組合物及方法
CA2783372C (en)	2009-12-07	2019-07-16	Muthiah Manoharan	Compositions for nucleic acid delivery
CN102712927B (zh)	2009-12-16	2017-12-01	库尔纳公司	通过抑制膜结合转录因子肽酶，位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病
AU2010330814B2 (en)	2009-12-18	2017-01-12	Acuitas Therapeutics Inc.	Methods and compositions for delivery of nucleic acids
KR101891352B1 (ko)	2009-12-23	2018-08-24	큐알엔에이, 인크.	간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
JP6031356B2 (ja)	2009-12-23	2016-11-24	カッパーアールエヌエー，インコーポレイテッド	Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
KR101838305B1 (ko)	2009-12-29	2018-03-13	큐알엔에이, 인크.	ＮＲＦ1(ＮｕｃｌｅａｒＲｅｓｐｉｒａｔｏｒｙＦａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
CA2785177C (en)	2009-12-29	2019-09-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
JP5886757B2 (ja)	2010-01-04	2016-03-16	カッパーアールエヌエー，インコーポレイテッド	インターフェロン調節因子８（ｉｒｆ８）に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子８（ｉｒｆ８）関連疾患の治療
EP2521785B1 (de)	2010-01-06	2022-03-09	CuRNA, Inc.	Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
JP6027893B2 (ja)	2010-01-11	2016-11-16	カッパーアールエヌエー，インコーポレイテッド	性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
EP2524042A2 (de)	2010-01-12	2012-11-21	Yale University	Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
WO2011088391A2 (en) *	2010-01-14	2011-07-21	Haplomics, Inc.	Predicting and reducing alloimmunogenicity of protein therapeutics
EP2529015B1 (de)	2010-01-25	2017-11-15	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit rnase h1 mittels hemmung des natürlichen antisense-transkripts gegen rnase h1
WO2011094580A2 (en)	2010-01-28	2011-08-04	Alnylam Pharmaceuticals, Inc.	Chelated copper for use in the preparation of conjugated oligonucleotides
WO2011100131A2 (en)	2010-01-28	2011-08-18	Alnylam Pharmacuticals, Inc.	Monomers and oligonucleotides comprising cycloaddition adduct(s)
US9574191B2 (en)	2010-02-03	2017-02-21	The Board Of Regents Of The University Of Texas System	Selective inhibition of polyglutamine protein expression
CA2824843A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
KR101838308B1 (ko)	2010-02-22	2018-03-13	큐알엔에이, 인크.	피롤린-5-카르복실레이트 환원효소 1(ｐｙｃｒ1)에 대한 천연 안티센스 전사체의 억제에 의한 ｐｙｃｒ1과 관련된 질환의 치료
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
CA2787657A1 (en)	2010-02-23	2011-09-01	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
ES2743600T3 (es)	2010-03-12	2020-02-20	Brigham & Womens Hospital Inc	Métodos de tratamiento de los trastornos inflamatorios vasculares
US20130101512A1 (en)	2010-03-12	2013-04-25	Chad A. Mirkin	Crosslinked polynucleotide structure
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
AU2011230496B2 (en)	2010-03-26	2015-09-17	Integrated Dna Technologies, Inc.	Methods for enhancing nucleic acid hybridization
US8889350B2 (en)	2010-03-26	2014-11-18	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
US9506057B2 (en)	2010-03-26	2016-11-29	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
US20130281510A1 (en)	2010-03-29	2013-10-24	Kumamoto University	siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
US9102938B2 (en)	2010-04-01	2015-08-11	Alnylam Pharmaceuticals, Inc.	2′ and 5′ modified monomers and oligonucleotides
AU2011237630B2 (en)	2010-04-06	2016-01-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of CD274/PD-L1 gene
TWI644675B (zh)	2010-04-09	2018-12-21	可娜公司	藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
US20110269194A1 (en)	2010-04-20	2011-11-03	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
US20130260460A1 (en)	2010-04-22	2013-10-03	Isis Pharmaceuticals Inc	Conformationally restricted dinucleotide monomers and oligonucleotides
US9725479B2 (en)	2010-04-22	2017-08-08	Ionis Pharmaceuticals, Inc.	5′-end derivatives
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
US9127033B2 (en)	2010-04-28	2015-09-08	Isis Pharmaceuticals, Inc.	5′ modified nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (de)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modifizierte nukleoside und daraus hergestellte oligomere verbindungen
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
ES2625689T3 (es)	2010-04-29	2017-07-20	Ionis Pharmaceuticals, Inc.	Modulación de la expresión de transtiretina
RU2693462C2 (ru)	2010-05-03	2019-07-03	Курна, Инк.	Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
CN102958941A (zh)	2010-05-03	2013-03-06	霍夫曼-拉罗奇有限公司	用于肿瘤诊断和治疗的组合物和方法
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
EP2576783B1 (de)	2010-05-26	2017-11-29	CuRNA, Inc.	Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
AU2011261434B2 (en)	2010-06-02	2015-11-26	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2802049C (en)	2010-06-07	2018-07-10	Firefly Bioworks, Inc.	Scanning multifunctional particles
EP2580228B1 (de)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
WO2011156713A1 (en)	2010-06-11	2011-12-15	Vanderbilt University	Multiplexed interferometric detection system and method
US20130236968A1 (en)	2010-06-21	2013-09-12	Alnylam Pharmaceuticals, Inc.	Multifunctional copolymers for nucleic acid delivery
WO2011163466A1 (en)	2010-06-23	2011-12-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (nrg-1)
CA2805318A1 (en)	2010-07-14	2012-01-19	Curna, Inc.	Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
US20130225659A1 (en)	2010-07-19	2013-08-29	Isis Pharmaceuticals, Inc.	Modulation of nuclear-retained rna
US20130323269A1 (en)	2010-07-30	2013-12-05	Muthiah Manoharan	Methods and compositions for delivery of active agents
WO2012016188A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
WO2012021554A1 (en)	2010-08-09	2012-02-16	Yale University	Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
CA2809457C (en)	2010-09-07	2019-07-30	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
SG10201508118WA (en)	2010-09-30	2015-11-27	Agency Science Tech & Res	Methods and reagents for detection and treatment of esophageal metaplasia
EP2625197B1 (de)	2010-10-05	2016-06-29	Genentech, Inc.	Smoothened-mutant und verfahren zu seiner anwendung
ES2640755T3 (es)	2010-10-06	2017-11-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
US9222088B2 (en)	2010-10-22	2015-12-29	Curna, Inc.	Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
DK2633052T3 (en)	2010-10-27	2018-07-16	Curna Inc	TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
AU2011325956B2 (en)	2010-11-12	2016-07-14	The General Hospital Corporation	Polycomb-associated non-coding RNAs
WO2012068405A2 (en)	2010-11-17	2012-05-24	Isis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
EP2643463B1 (de)	2010-11-23	2017-09-27	CuRNA, Inc.	Behandlung von nanog-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen nanog
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
US9127275B2 (en)	2010-12-10	2015-09-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
EP2649182A4 (de)	2010-12-10	2015-05-06	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
JP5902197B2 (ja)	2011-01-11	2016-04-13	アルニラム・ファーマシューティカルズ・インコーポレーテッド	Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
US9045749B2 (en)	2011-01-14	2015-06-02	The General Hospital Corporation	Methods targeting miR-128 for regulating cholesterol/lipid metabolism
EP2670404B1 (de)	2011-02-02	2018-08-29	The Trustees of Princeton University	Sirtuin-modulatoren als modulatoren der virusproduktion
JP6177692B2 (ja)	2011-02-02	2017-08-09	エクスカリアード・ファーマシューティカルズ，インク	結合組織増殖因子（ｃｔｇｆ）をターゲティングするアンチセンス化合物を用いた、ケロイドまたは肥厚性瘢痕の治療法
MX2013008944A (es)	2011-02-03	2014-01-08	Mirna Therapeutics Inc	Mimeticos sinteticos de mir-124.
EP3178932A1 (de)	2011-02-03	2017-06-14	Mirna Therapeutics, Inc.	Synthetische mimetika von mir-34
EP3467109A1 (de)	2011-02-08	2019-04-10	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
EP2678026B1 (de)	2011-02-21	2016-05-18	The University of Zurich	Ankyrin-g zur verwendung in der behandlung von neurodegenerativer erkrankungen
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
EP2691121A4 (de)	2011-03-29	2015-08-26	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur hemmung der tmprss6-genexpression
US10086043B2 (en)	2011-04-03	2018-10-02	The General Hospital Corporation	Efficient protein expression in vivo using modified RNA (MOD-RNA)
JP5879667B2 (ja)	2011-04-20	2016-03-08	メサバイオテック，インク．	核酸の検出および同定のための一体型デバイス
WO2012149154A1 (en)	2011-04-26	2012-11-01	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
JP6188686B2 (ja)	2011-06-09	2017-08-30	カッパーアールエヌエー，インコーポレイテッド	フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2838984A1 (en)	2011-06-10	2012-12-13	Isis Pharmaceuticals, Inc.	Methods for modulating kallikrein (klkb1) expression
CN103890000B (zh)	2011-06-21	2017-09-01	阿尔尼拉姆医药品有限公司	血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
KR20260004562A (ko)	2011-06-21	2026-01-08	알닐람 파마슈티칼스 인코포레이티드	아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
WO2012177949A2 (en)	2011-06-21	2012-12-27	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibition of expression of protein c (proc) genes
EP2723390B1 (de)	2011-06-23	2017-12-27	Alnylam Pharmaceuticals, Inc.	Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
WO2013003808A1 (en)	2011-06-29	2013-01-03	Isis Pharmaceuticals, Inc.	Methods for modulating kallikrein (klkb1) expression
US20140328811A1 (en)	2011-08-01	2014-11-06	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
EP2742056B2 (de)	2011-08-11	2020-06-10	Ionis Pharmaceuticals, Inc.	Selektive antisense-verbindungen und ihre verwendungen
US9580708B2 (en)	2011-09-14	2017-02-28	Rana Therapeutics, Inc.	Multimeric oligonucleotides compounds
ES2856091T3 (es)	2011-09-14	2021-09-27	Univ Northwestern	Nanoconjugados capaces de atravesar la barrera hematoencefálica
WO2013040548A2 (en)	2011-09-17	2013-03-21	Yale University	Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
AU2012315965A1 (en)	2011-09-27	2014-04-03	Alnylam Pharmaceuticals, Inc.	Di-aliphatic substituted PEGylated lipids
US10184151B2 (en)	2011-10-11	2019-01-22	The Brigham And Women's Hospital, Inc.	Micrornas in neurodegenerative disorders
JP6532678B2 (ja)	2011-10-14	2019-06-19	ジェネンテック，インコーポレイテッド	抗ＨｔｒＡ１抗体及び使用方法
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
KR20140102759A (ko)	2011-12-16	2014-08-22	모더나 세라퓨틱스, 인코포레이티드	변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
JP6280045B2 (ja)	2011-12-22	2018-02-14	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	肺腺癌内転移関連性転写物１（ｍｅｔａｓｔａｓｉｓ−ａｓｓｏｃｉａｔｅｄ−ｉｎ−ｌｕｎｇ−ａｄｅｎｏｃａｒｃｉｎｏｍａ−ｔｒａｎｓｃｒｉｐｔ−１：ｍａｌａｔ−１）の発現調節法
EP2812342B1 (de)	2012-02-08	2017-11-15	Ionis Pharmaceuticals, Inc.	Modulation von rna durch wiederholtes targeting
EP2825672B1 (de)	2012-03-13	2019-02-13	Swift Biosciences, Inc.	Verfahren und zusammensetzungen für grössenkontrolliertes homopolymer-tailing von substratpolynucleotiden mittels einer nucleinsäurepolymerase
HUE040179T2 (hu)	2012-03-15	2019-02-28	Curna Inc	Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
WO2013138662A1 (en)	2012-03-16	2013-09-19	4S3 Bioscience, Inc.	Antisense conjugates for decreasing expression of dmpk
WO2013142514A1 (en)	2012-03-19	2013-09-26	Isis Pharmaceuticals, Inc.	Methods and compositions for modulating alpha-1-antitrypsin expression
HK1206612A1 (en)	2012-04-02	2016-01-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of secreted proteins
EP2834259A4 (de)	2012-04-02	2016-08-24	Moderna Therapeutics Inc	Modifizierte polynukleotide
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013159108A2 (en)	2012-04-20	2013-10-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
JP2015518485A (ja)	2012-04-20	2015-07-02	アプタミアールセラピューティクスインコーポレイテッド	熱発生のｍｉＲＮＡ調節剤
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
EP3597741A1 (de)	2012-04-27	2020-01-22	Duke University	Genetische korrektur mutierter gene
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
SG11201407483YA (en)	2012-05-16	2014-12-30	Rana Therapeutics Inc	Compositions and methods for modulating smn gene family expression
EP3511416A1 (de)	2012-05-16	2019-07-17	Translate Bio MA, Inc.	Zusammensetzungen und verfahren zur modulation von genexpression
EP2852606B1 (de)	2012-05-22	2019-08-07	Ionis Pharmaceuticals, Inc.	Modulation der durch verstärker-rns vermittelten genexpression
ES2809199T3 (es)	2012-06-25	2021-03-03	Ionis Pharmaceuticals Inc	Modulación de la expresión de UBE3A-ATS
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
EP2877579B1 (de)	2012-07-27	2019-12-18	Ionis Pharmaceuticals, Inc.	Modulation von mit dem reninangiotensinsystem (ras) assoziierten erkrankungen durch angiotensinogen
WO2014022852A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US9403865B2 (en)	2012-08-15	2016-08-02	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
WO2014045126A2 (en)	2012-09-18	2014-03-27	Uti Limited Partnership	Treatment of pain by inhibition of usp5 de-ubiquitinase
US9175291B2 (en)	2012-10-11	2015-11-03	Isis Pharmaceuticals Inc.	Modulation of androgen receptor expression
EP2906699A4 (de)	2012-10-11	2016-06-08	Ionis Pharmaceuticals Inc	Oligomere verbindungen mit bicyclischen nukleosiden und verwendungen davon
WO2014059364A1 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Methods of treating kennedy's disease
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CA3201145A1 (en)	2012-10-26	2014-05-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
HK1214831A1 (zh)	2012-11-05	2016-08-05	Foundation Medicine, Inc.	新型融合分子及其应用
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
US9597380B2 (en)	2012-11-26	2017-03-21	Modernatx, Inc.	Terminally modified RNA
WO2014089541A2 (en)	2012-12-07	2014-06-12	Haplomics, Inc.	Factor viii mutation repair and tolerance induction
JP2016504050A (ja)	2013-01-17	2016-02-12	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
US10980804B2 (en)	2013-01-18	2021-04-20	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
US9701708B2 (en)	2013-01-31	2017-07-11	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified coupling protocols
KR20200123263A (ko)	2013-02-14	2020-10-28	아이오니스 파마수티컬즈, 인코포레이티드	지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
WO2014134179A1 (en)	2013-02-28	2014-09-04	The Board Of Regents Of The University Of Texas System	Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
WO2014159813A1 (en)	2013-03-13	2014-10-02	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
US10258698B2 (en)	2013-03-14	2019-04-16	Modernatx, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CN114015692B (zh)	2013-03-14	2024-12-31	阿尔尼拉姆医药品有限公司	补体组分C5 iRNA组合物及其使用方法
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
CA2918194C (en)	2013-03-27	2022-12-06	The General Hospital Corporation	Methods and agents for treating alzheimer's disease
JP2016522679A (ja)	2013-04-04	2016-08-04	プレジデントアンドフェローズオブハーバードカレッジ	ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
WO2014172698A1 (en)	2013-04-19	2014-10-23	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
PE20152002A1 (es)	2013-05-01	2016-01-21	Isis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de ttr y vhb
TWI727917B (zh)	2013-05-22	2021-05-21	美商阿尼拉製藥公司	ＴＭＰＲＳＳ６ｉＲＮＡ組成物及其使用方法
EP3412774A1 (de)	2013-05-22	2018-12-12	Alnylam Pharmaceuticals, Inc.	Serpina1-irna-zusammensetzungen und verfahren zur verwendung davon
EP3004396B1 (de)	2013-06-06	2019-10-16	The General Hospital Corporation	Zusammensetzungen zur krebsbehandlung
DK3007704T3 (da)	2013-06-13	2021-03-29	Antisense Therapeutics Ltd	Kombinationsterapi til akromegali
WO2014205449A2 (en)	2013-06-21	2014-12-24	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
WO2015002971A2 (en)	2013-07-02	2015-01-08	Isis Pharmaceuticals, Inc.	Modulators of growth hormone receptor
DK3019619T3 (da)	2013-07-11	2021-10-11	Modernatx Inc	Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
WO2015017694A1 (en) *	2013-07-31	2015-02-05	Regents Of The University Of California	Dna double-write/double binding identity
WO2015021432A1 (en)	2013-08-08	2015-02-12	The Scripps Research Institute	A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
RU2712559C9 (ru)	2013-08-28	2020-10-08	Ионис Фармасьютикалз, Инк.	Модуляция экспрессии прекалликреина (пкк)
EP3041938A1 (de)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Kreisförmige polynukleotide
AU2014315287A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Chimeric polynucleotides
CN112359042A (zh)	2013-09-13	2021-02-12	Ionis制药公司	补体因子b的调节剂
TWI669393B (zh)	2013-10-02	2019-08-21	艾爾妮蘭製藥公司	抑制ｌｅｃｔ２基因表現之組合物及方法
EP3052521A1 (de)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
BR122020001264B1 (pt)	2013-10-04	2022-11-22	Icahn School Of Medicine At Mount Sinai	Ácido ribonucleico de fita dupla (dsrna) para inibição da expressão de alas1, composição farmacêutica para inibição da expressão de um gene alas1, métodos de inibição da expressão de alas1 em uma célula e para diminuir um nível de uma porfirina ou de um precursor de porfirina em uma célula, usos de um dsrna, método para avaliar o nível de mrna de alas1 extracelular em circulação em um indivíduo, composição e uso da mesma
EP3055426B1 (de)	2013-10-09	2019-06-19	The United States of America as represented by The Secretary Department of Health and Human Services	Nachweis von hepatitis delta virus (hdv) zur diagnose und behandlung von sjögren-syndrom und lymphom
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
US9758546B2 (en)	2013-10-21	2017-09-12	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
CA2928779A1 (en)	2013-10-21	2015-04-30	The General Hospital Corporation	Methods relating to circulating tumor cell clusters and the treatment of cancer
US10301622B2 (en)	2013-11-04	2019-05-28	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
KR102507624B1 (ko)	2013-11-22	2023-03-09	미나 테라퓨틱스 리미티드	Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
JP6527516B2 (ja)	2013-12-03	2019-06-05	ノースウェスタンユニバーシティ	リポソーム粒子、前述のものを作製する方法及びその使用
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
IL314045A (en)	2013-12-12	2024-09-01	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
EP3082840B1 (de)	2013-12-20	2021-03-24	The General Hospital Corporation	Verfahren und tests im zusammenhang mit zirkulierenden tumorzellen
CN105814204B (zh)	2013-12-24	2020-04-28	Ionis制药公司	促血管生成素样3表达的调节
CA2937539A1 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
KR102592370B1 (ko)	2014-02-11	2023-10-25	알닐람 파마슈티칼스 인코포레이티드	케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
WO2015142910A1 (en)	2014-03-17	2015-09-24	Isis Pharmaceuticals, Inc.	Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
EP3119888B1 (de)	2014-03-19	2021-07-28	Ionis Pharmaceuticals, Inc.	Zusammensetzungen zur modulierung der ataxin-2-expression
US10006027B2 (en)	2014-03-19	2018-06-26	Ionis Pharmaceuticals, Inc.	Methods for modulating Ataxin 2 expression
SI3757214T1 (sl)	2014-04-01	2022-08-31	Biogen Ma Inc.	Sestave za moduliranje izražanja SOD-1
EP3129493B1 (de)	2014-04-09	2021-07-07	The Scripps Research Institute	Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
MA39835A (fr)	2014-04-17	2017-02-22	Biogen Ma Inc	Compositions et procédés de modulation de l'épissage du smn2 chez un patient
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
ES2844593T3 (es)	2014-05-01	2021-07-22	Ionis Pharmaceuticals Inc	Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
HUE052709T2 (hu)	2014-05-01	2021-05-28	Ionis Pharmaceuticals Inc	Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
EP3137115B1 (de)	2014-05-01	2020-10-14	Ionis Pharmaceuticals, Inc.	Verfahren zur synthese von reaktiven konjugatclustern
ES2812099T3 (es)	2014-05-01	2021-03-16	Ionis Pharmaceuticals Inc	Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
RS59182B1 (sr)	2014-05-01	2019-10-31	Ionis Pharmaceuticals Inc	Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
WO2015171918A2 (en)	2014-05-07	2015-11-12	Louisiana State University And Agricultural And Mechanical College	Compositions and uses for treatment thereof
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
MX382901B (es)	2014-05-22	2025-03-13	Alnylam Pharmaceuticals Inc	Composiciones de angiotensinogeno (agt) arni y métodos de uso de las mismas.
WO2015187541A1 (en)	2014-06-02	2015-12-10	Children's Medical Center Corporation	Methods and compositions for immunomodulation
CN106661580B (zh)	2014-06-10	2022-02-15	鹿特丹伊拉斯谟大学医疗中心	用于治疗庞帕病的反义寡核苷酸
EP3760208B1 (de)	2014-06-25	2024-05-29	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
EP3169693B1 (de)	2014-07-16	2022-03-09	ModernaTX, Inc.	Chimäre polynukleotide
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
EP3171895A1 (de)	2014-07-23	2017-05-31	Modernatx, Inc.	Modifizierte polynukleotide zur herstellung von intrabodys
AU2015298263B2 (en)	2014-07-31	2020-05-14	Anji Pharmaceuticals, Inc.	ApoE mimetic peptides and higher potency to clear plasma cholesterol
AU2015305482B2 (en)	2014-08-19	2021-04-01	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
LT3185957T (lt)	2014-08-29	2022-09-26	Alnylam Pharmaceuticals, Inc.	Patisiranas, skirtas naudoti transtiretino amiloidozei gydyti
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP3185910A4 (de)	2014-08-29	2018-01-10	Children's Medical Center Corporation	Verfahren und zusammensetzungen zur krebsbehandlung
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
US10436802B2 (en)	2014-09-12	2019-10-08	Biogen Ma Inc.	Methods for treating spinal muscular atrophy
KR20170058979A (ko)	2014-09-18	2017-05-29	더 유니버시티 오브 브리티쉬 콜롬비아	헌팅턴병 일배체형에 대한 대립 유전자-특이적 치료
WO2016049512A1 (en)	2014-09-26	2016-03-31	University Of Massachusetts	Rna-modulating agents
TWI755351B (zh)	2014-10-10	2022-02-21	美商艾爾妮蘭製藥公司	用於抑制ｈａｏ１（羥酸氧化酶１（乙醇酸鹽氧化酶））基因表現的組合物及方法
EP3207138B1 (de)	2014-10-17	2020-07-15	Alnylam Pharmaceuticals, Inc.	Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
WO2016069694A2 (en)	2014-10-30	2016-05-06	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
US20170312297A1 (en)	2014-11-10	2017-11-02	Glaxosmithkline Intellectual Property (No. 2) Limited	Long Acting Pharmaceutical Compositions For Hepatitis C
SG11201703646SA (en)	2014-11-10	2017-06-29	Glaxosmithkline Intellectual Property (No 2) Ltd	Combination long acting compositions and methods for hepatitis c
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
CN107250362B (zh)	2014-11-17	2021-10-22	阿尔尼拉姆医药品有限公司	载脂蛋白C3(APOC3)iRNA组合物及其使用方法
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10400243B2 (en)	2014-11-25	2019-09-03	Ionis Pharmaceuticals, Inc.	Modulation of UBE3A-ATS expression
AU2015360794B2 (en)	2014-12-08	2021-07-08	The Board Of Regents Of The University Of Texas System	Lipocationic polymers and uses thereof
US20170369872A1 (en)	2014-12-18	2017-12-28	Alnylam Pharmaceuticals, Inc.	Reversir tm compounds
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en)	2015-01-06	2020-10-06	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
WO2016115490A1 (en)	2015-01-16	2016-07-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of dux4
WO2016118812A1 (en)	2015-01-23	2016-07-28	Vanderbilt University	A robust interferometer and methods of using same
JP6929791B2 (ja)	2015-02-09	2021-09-01	デュークユニバーシティ	エピゲノム編集のための組成物および方法
JP2018510621A (ja)	2015-02-13	2018-04-19	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
US10450342B2 (en)	2015-02-23	2019-10-22	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
US12129471B2 (en)	2015-02-23	2024-10-29	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of human genetic diseases including hemoglobinopathies
ES2848377T3 (es)	2015-02-26	2021-08-09	Ionis Pharmaceuticals Inc	Moduladores específicos de alelo de RODOPSINA P23H
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
CN115537396A (zh)	2015-03-27	2022-12-30	哈佛学院校长同事会	经过修饰的t细胞及其制备和使用方法
WO2016161429A1 (en)	2015-04-03	2016-10-06	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating tmprss6 expression
WO2016164463A1 (en)	2015-04-07	2016-10-13	The General Hospital Corporation	Methods for reactivating genes on the inactive x chromosome
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
EP3722424A1 (de)	2015-04-16	2020-10-14	Ionis Pharmaceuticals, Inc.	Zusammensetzungen zur modulierung der c9orf72 -expression
WO2016172724A1 (en)	2015-04-24	2016-10-27	Mesa Biotech, Inc.	Fluidic test cassette
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
WO2016210241A1 (en)	2015-06-26	2016-12-29	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
IL318703A (en)	2015-06-29	2025-03-01	Caris Science Inc	Therapeutic oligonucleotides
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
US11053495B2 (en)	2015-07-17	2021-07-06	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
US10941176B2 (en)	2015-07-28	2021-03-09	Caris Science, Inc.	Therapeutic oligonucleotides
WO2017021961A1 (en)	2015-08-04	2017-02-09	Yeda Research And Development Co. Ltd.	Methods of screening for riboswitches and attenuators
SG10202007937SA (en)	2015-09-02	2020-09-29	Alnylam Pharmaceuticals Inc	PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11247968B2 (en)	2015-09-14	2022-02-15	The Board Of Regents Of The University Of Texas System	Lipocationic dendrimers and uses thereof
US20190048340A1 (en)	2015-09-24	2019-02-14	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
JP2018530325A (ja)	2015-10-08	2018-10-18	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	アンジオテンシノーゲンの発現を調節するための化合物及び方法
US11970710B2 (en)	2015-10-13	2024-04-30	Duke University	Genome engineering with Type I CRISPR systems in eukaryotic cells
EP4279084B1 (de)	2015-10-28	2025-06-11	Vertex Pharmaceuticals Inc.	Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
NZ741780A (en)	2015-10-30	2019-11-29	Genentech Inc	Anti-htra1 antibodies and methods of use thereof
WO2017075670A1 (en)	2015-11-05	2017-05-11	Children's Hospital Los Angeles	"mobilizing leukemia cells"
WO2017077386A1 (en)	2015-11-06	2017-05-11	Crispr Therapeutics Ag	Materials and methods for treatment of glycogen storage disease type 1a
KR20250078597A (ko)	2015-11-06	2025-06-02	아이오니스 파마수티컬즈, 인코포레이티드	아포리포프로테인 (a) 발현 조정
WO2017087708A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
KR102787119B1 (ko)	2015-11-30	2025-03-27	듀크 유니버시티	유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
JP6932698B2 (ja)	2015-12-01	2021-09-08	クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲＴｈｅｒａｐｅｕｔｉｃｓＡＧ	アルファ１アンチトリプシン欠乏症の治療のための材料および方法
WO2017096395A1 (en)	2015-12-04	2017-06-08	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
KR20210157474A (ko)	2015-12-07	2021-12-28	젠자임 코포레이션	Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
EP3387127A1 (de)	2015-12-07	2018-10-17	Erasmus University Medical Center Rotterdam	Enzymatische ersatztherapie und antisense-therapie für pompe-krankheit
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
EP3394260B1 (de)	2015-12-23	2021-02-17	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyothrophischer lateraler sklerose und/oder frontotemporaler demenz
WO2017117496A1 (en)	2015-12-31	2017-07-06	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
AU2017205462A1 (en)	2016-01-05	2018-06-07	Ionis Pharmaceuticals, Inc.	Methods for reducing LRRK2 expression
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
EP3411078A1 (de)	2016-02-02	2018-12-12	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn-syndrom
EP3411396A1 (de)	2016-02-04	2018-12-12	Curis, Inc.	Smoothened-mutant und verfahren zur verwendung davon
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017147087A1 (en)	2016-02-25	2017-08-31	The Brigham And Women's Hospital, Inc.	Treatment methods for fibrosis targeting smoc2
US10961271B2 (en)	2016-03-16	2021-03-30	Ionis Pharmaceuticals, Inc.	Methods of modulating KEAP1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
US11083799B2 (en)	2016-03-16	2021-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
US10731166B2 (en)	2016-03-18	2020-08-04	Caris Science, Inc.	Oligonucleotide probes and uses thereof
US20190127713A1 (en)	2016-04-13	2019-05-02	Duke University	Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
AU2017252023B2 (en)	2016-04-18	2024-05-02	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
EP3458032A4 (de)	2016-05-16	2019-12-25	The Board of Regents of The University of Texas System	Kationische sulfonamid-aminolipide und amphiphile zwitterionische aminolipide
IL298701B2 (en)	2016-05-25	2024-03-01	Caris Science Inc	Oligonucleotide probes and uses thereof
EP3469083A1 (de)	2016-06-10	2019-04-17	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
CA3023514A1 (en)	2016-06-17	2017-12-21	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
ES2929047T3 (es)	2016-06-24	2022-11-24	Scripps Research Inst	Transportador de nucleósido trifosfato novedoso y usos del mismo
US11174469B2 (en)	2016-06-29	2021-11-16	Crispr Therapeutics Ag	Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
CA3029119A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
US11427838B2 (en)	2016-06-29	2022-08-30	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
US11801313B2 (en)	2016-07-06	2023-10-31	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
CN109843914B (zh)	2016-07-06	2024-03-15	沃泰克斯药物股份有限公司	用于治疗疼痛相关病症的材料和方法
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
US11253601B2 (en)	2016-07-11	2022-02-22	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
EP4275747A3 (de)	2016-07-19	2024-01-24	Duke University	Therapeutische anwendungen von cpf1-basierter genomeditierung
KR20190031306A (ko)	2016-07-21	2019-03-25	맥스시티 인코포레이티드	게놈 dna를 변경하기 위한 방법 및 조성물
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
KR20190065341A (ko)	2016-10-06	2019-06-11	아이오니스 파마수티컬즈, 인코포레이티드	올리고머 화합물들의 접합 방법
WO2018081817A2 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
WO2018102745A1 (en)	2016-12-02	2018-06-07	Cold Spring Harbor Laboratory	Modulation of lnc05 expression
AU2017378153B2 (en)	2016-12-13	2024-03-28	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
SG10201913552UA (en)	2016-12-16	2020-03-30	Alnylam Pharmaceuticals Inc	Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
WO2018136758A1 (en)	2017-01-23	2018-07-26	Regeneron Pharmaceuticals, Inc.	Hsd17b13 variants and uses thereof
US11407997B2 (en)	2017-02-22	2022-08-09	Crispr Therapeutics Ag	Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
WO2018154462A2 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US20200040061A1 (en)	2017-02-22	2020-02-06	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
US11920148B2 (en)	2017-02-22	2024-03-05	Crispr Therapeutics Ag	Compositions and methods for gene editing
WO2018154439A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
US20180284123A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
US11484570B2 (en)	2017-04-14	2022-11-01	University Of Massachusetts	Targeting cell tropism receptors to inhibit cytomegalovirus infection
CN118384268A (zh)	2017-04-18	2024-07-26	阿尔尼拉姆医药品有限公司	具有乙肝病毒（hbv）感染的受试者的治疗方法
JP7801082B2 (ja)	2017-04-20	2026-01-16	シンセナアーゲー	トリシクロｄｎａヌクレオシドを含む改変オリゴマー化合物およびその使用
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
WO2018195486A1 (en)	2017-04-21	2018-10-25	The Broad Institute, Inc.	Targeted delivery to beta cells
IL270415B2 (en)	2017-05-12	2024-08-01	Crispr Therapeutics Ag	Materials and methods for cell engineering and their uses in immuno-oncology
US20200163987A1 (en)	2017-07-10	2020-05-28	Genzyme Corporation	Methods and compositions for treating a bleeding event in a subject having hemophilia
TW202426655A (zh)	2017-07-11	2024-07-01	美商新索思股份有限公司	非天然核苷酸之導入及其方法
KR20200028997A (ko)	2017-07-13	2020-03-17	노오쓰웨스턴 유니버시티	올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
JP7277432B2 (ja)	2017-07-13	2023-05-19	アルナイラムファーマシューティカルズ，インコーポレイテッド	乳酸脱水素酵素Ａ（ＬＤＨＡ）ｉＲＮＡ組成物及びその使用方法
MA49767A (fr)	2017-08-03	2021-05-26	Synthorx Inc	Conjugués de cytokine pour le traitement de maladies auto-immunes
EP3668984A4 (de)	2017-08-18	2021-09-08	Ionis Pharmaceuticals, Inc.	Modulation des notch-signalweges zur behandlung von atemwegserkrankungen
EP4219715A3 (de)	2017-09-08	2023-09-06	MiNA Therapeutics Limited	Stabilisierte cebpa-sarna-zusammensetzungen und verfahren zur verwendung
EP4183882A1 (de)	2017-09-08	2023-05-24	MiNA Therapeutics Limited	Stabilisierte hnf4a-sarna-zusammensetzungen und verfahren zur verwendung
WO2019051173A1 (en)	2017-09-08	2019-03-14	Ionis Pharmaceuticals, Inc.	MODULATORS OF SMAD7 EXPRESSION
US11999953B2 (en)	2017-09-13	2024-06-04	The Children's Medical Center Corporation	Compositions and methods for treating transposon associated diseases
BR112020005230A2 (pt)	2017-09-19	2020-09-24	Alnylam Pharmaceuticals, Inc.	composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
CN111684070A (zh)	2017-10-17	2020-09-18	克里斯珀医疗股份公司	用于a型血友病基因编辑的组合物和方法
WO2019081982A1 (en)	2017-10-26	2019-05-02	Crispr Therapeutics Ag	SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
SG11202002940QA (en)	2017-11-01	2020-04-29	Alnylam Pharmaceuticals Inc	Complement component c3 irna compositions and methods of use thereof
US20210363521A1 (en)	2017-11-09	2021-11-25	Vertex Pharmaceuticals Incorporated	CRISPR/CAS Systems For Treatment of DMD
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
EP3714055A1 (de)	2017-11-21	2020-09-30	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von autosomal-dominanter retinitis pigmentosa
WO2019104155A2 (en)	2017-11-22	2019-05-31	The University Of Chicago	Chemical probe-dependent evaluation of protein activity and uses thereof
SG11202005147WA (en)	2017-12-05	2020-06-29	Vertex Pharma	Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
US11578323B2 (en)	2017-12-14	2023-02-14	Bayer Healthcare Llc	RNA-programmable endonuclease systems and their use in genome editing and other applications
BR112020012088A2 (pt)	2017-12-18	2020-11-17	Alnylam Pharmaceuticals, Inc.	composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
AU2018393050A1 (en)	2017-12-21	2020-06-18	Bayer Healthcare Llc	Materials and methods for treatment of Usher Syndrome Type 2A
WO2019123430A1 (en)	2017-12-21	2019-06-27	Casebia Therapeutics Llp	Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
KR102776907B1 (ko)	2017-12-29	2025-03-11	더 스크립스 리서치 인스티튜트	비천연 염기쌍 조성물 및 사용 방법
US12178855B2 (en)	2018-01-10	2024-12-31	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
EP3737762A1 (de)	2018-01-12	2020-11-18	CRISPR Therapeutics AG	Zusammensetzungen und verfahren zur geneditierung von genen durch transferrin-targeting
MX2020007369A (es)	2018-01-15	2020-10-28	Ionis Pharmaceuticals Inc	Moduladores de la expresion de dnm2.
US12509492B2 (en)	2018-01-19	2025-12-30	Duke University	Genome engineering with CRISPR-Cas systems in eukaryotes
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
MA51787A (fr)	2018-02-05	2020-12-16	Vertex Pharma	Substances et méthodes de traitement d'hémoglobinopathies
WO2019150203A1 (en)	2018-02-05	2019-08-08	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
WO2019161310A1 (en)	2018-02-16	2019-08-22	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting fibrinogen-alpha
CN112004547A (zh)	2018-02-26	2020-11-27	新索思股份有限公司	Il-15缀合物及其用途
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
EP3759127A4 (de)	2018-03-02	2022-03-30	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation des amyloid-beta-vorläuferproteins
CA3092497A1 (en)	2018-03-19	2019-09-26	Crispr Therapeutics Ag	Novel rna-programmable endonuclease systems and uses thereof
US11661601B2 (en)	2018-03-22	2023-05-30	Ionis Pharmaceuticals, Inc.	Methods for modulating FMR1 expression
JP7474702B2 (ja)	2018-03-28	2024-04-25	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法
CA3095545A1 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
US20210155959A1 (en)	2018-04-06	2021-05-27	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
PE20201349A1 (es)	2018-04-11	2020-11-30	Ionis Pharmaceuticals Inc	Moduladores de la expresion de ezh2
US11566246B2 (en)	2018-04-12	2023-01-31	Mina Therapeutics Limited	SIRT1-saRNA compositions and methods of use
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
CN112041436A (zh)	2018-04-27	2020-12-04	西雅图儿童医院（Dba西雅图儿童研究所）	雷帕霉素抗性细胞
MX2020011570A (es)	2018-05-07	2020-11-24	Alnylam Pharmaceuticals Inc	Administracion extrahepatica.
SG11202010012PA (en)	2018-05-09	2020-11-27	Ionis Pharmaceuticals Inc	Compounds and methods for reducing fxi expression
WO2019217708A1 (en)	2018-05-09	2019-11-14	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing atxn3 expression
EP3790893A4 (de)	2018-05-11	2022-03-16	University Of Massachusetts	Verfahren zur verbesserung der leptinempfindlichkeit zur behandlung von fettleibigkeit und diabetes
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
AU2019287635B2 (en)	2018-06-14	2026-02-12	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing STMN2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
WO2020018558A1 (en)	2018-07-17	2020-01-23	Aronora, Inc.	Methods for safely reducing thrombopoietin
CA3106986A1 (en)	2018-07-25	2020-01-30	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing atxn2 expression
MX2021001056A (es)	2018-08-13	2021-04-12	Alnylam Pharmaceuticals Inc	Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
EP3837367A1 (de)	2018-08-16	2021-06-23	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
US12281308B2 (en)	2018-08-29	2025-04-22	University Of Massachusetts	Inhibition of protein kinases to treat Friedreich ataxia
AU2019339509A1 (en)	2018-09-14	2021-05-13	Northwestern University	Programming protein polymerization with DNA
US20210332367A1 (en)	2018-09-18	2021-10-28	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3856931B1 (de)	2018-09-25	2023-10-11	Co-Diagnostics, Inc.	Allelspezifische konstruktion von kooperativen primern für verbesserte genotypisierung von nukleinsäurevarianten
WO2020069055A1 (en)	2018-09-28	2020-04-02	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
JP7520826B2 (ja)	2018-10-17	2024-07-23	クリスパー・セラピューティクス・アクチェンゲゼルシャフト	導入遺伝子を送達するための組成物および方法
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
CN113260374A (zh)	2018-11-08	2021-08-13	新索思股份有限公司	白介素10缀合物及其用途
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
AU2019380940A1 (en)	2018-11-15	2021-06-03	Ionis Pharmaceuticals, Inc.	Modulators of IRF5 expression
EP3884053A4 (de)	2018-11-21	2023-02-01	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur verringerung der prionenexpression
CA3121191A1 (en)	2018-11-28	2020-06-04	Crispr Therapeutics Ag	Optimized mrna encoding cas9 for use in lnps
EP3894559A4 (de)	2018-12-03	2023-04-05	Triplet Therapeutics, Inc.	Verfahren zur behandlung von störungen der trinukleotid-repeat-expansion im zusammenhang mit mlh3-aktivität
WO2020118259A1 (en)	2018-12-06	2020-06-11	Northwestern University	Protein crystal engineering through dna hybridization interactions
DK4285929T3 (da)	2018-12-20	2025-12-22	Humabs Biomed Sa	Kombinationsterapi mod hbv
EP3898977A1 (de)	2018-12-20	2021-10-27	Praxis Precision Medicines, Inc.	Zusammensetzungen und verfahren zur behandlung von kcnt1-assoziierten erkrankungen
CA3126933A1 (en)	2019-01-16	2020-07-23	Genzyme Corporation	Serpinc1 irna compositions and methods of use thereof
TW202214854A (zh)	2019-01-31	2022-04-16	美商Ionis製藥公司	Yap1表現之調節劑
CA3127689A1 (en)	2019-02-06	2020-08-13	Synthorx, Inc.	Il-2 conjugates and methods of use thereof
WO2020168362A1 (en)	2019-02-15	2020-08-20	Crispr Therapeutics Ag	Gene editing for hemophilia a with improved factor viii expression
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
MX2021010152A (es)	2019-02-27	2021-09-14	Ionis Pharmaceuticals Inc	Moduladores de la expresion de malat1.
SG11202109741VA (en)	2019-03-12	2021-10-28	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
EP3941483A4 (de)	2019-03-21	2023-10-18	Arnay Sciences, Llc	Antisense-oligonukleotide zur allelspezifität
WO2020203880A1 (ja)	2019-03-29	2020-10-08	田辺三菱製薬株式会社	Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物
MD3947684T2 (ro)	2019-03-29	2025-10-31	Ionis Pharmaceuticals Inc	Compuși și metode pentru modularea UBE3A-ATS
WO2020208361A1 (en)	2019-04-12	2020-10-15	Mina Therapeutics Limited	Sirt1-sarna compositions and methods of use
KR20220036914A (ko)	2019-05-13	2022-03-23	비르 바이오테크놀로지, 인코포레이티드	B형 간염 바이러스(hbv) 감염을 치료하기 위한 조성물 및 방법
AU2020279101B2 (en)	2019-05-17	2025-07-24	Alnylam Pharmaceuticals, Inc.	Oral delivery of oligonucleotides
IL288941B2 (en)	2019-06-14	2025-10-01	Scripps Research Inst	Reagents and methods for replication, transcription, and translation in semisynthetic organisms
EP4660307A2 (de)	2019-07-26	2025-12-10	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur gfap-modulation
WO2021022109A1 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030778A1 (en)	2019-08-15	2021-02-18	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds and uses thereof
WO2021030706A1 (en)	2019-08-15	2021-02-18	Synthorx, Inc.	Immuno oncology combination therapies with il-2 conjugates
US20220281911A1 (en)	2019-08-19	2022-09-08	Mina Therapeutics Limited	Oligonucleotide conjugate compositions and methods of use
US12344648B2 (en)	2019-08-23	2025-07-01	Synthrox, Inc.	IL-15 conjugates and uses thereof
MX2022002689A (es)	2019-09-03	2022-04-07	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
AU2020347154A1 (en)	2019-09-10	2022-03-03	Synthorx, Inc.	IL-2 conjugates and methods of use to treat autoimmune diseases
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
EP4038189A1 (de)	2019-10-04	2022-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
US12486512B2 (en)	2019-10-18	2025-12-02	Alnylam Pharmaceuticals, Inc.	Solute carrier family member iRNA compositions and methods of use thereof
AU2020369515A1 (en)	2019-10-22	2022-04-21	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
CN119499394A (zh)	2019-11-01	2025-02-25	阿尔尼拉姆医药品有限公司	亨廷顿（HTT）iRNA药剂组合物及其使用方法
WO2021087325A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
EP4054644A1 (de)	2019-11-04	2022-09-14	Synthorx, Inc.	Interleukin-10-konjugate und deren verwendungen
EP4055165A1 (de)	2019-11-06	2022-09-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen
EP4055166A2 (de)	2019-11-06	2022-09-14	Alnylam Pharmaceuticals, Inc.	Extrahepatische verabreichung
TWI877247B (zh)	2019-11-13	2025-03-21	美商阿尼拉製藥公司	用於治療血管收縮素原相關病症之方法及組成物
WO2021102373A1 (en)	2019-11-22	2021-05-27	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
PH12022551394A1 (en)	2019-12-13	2023-09-11	Alnylam Pharmaceuticals Inc	Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
EP4077674A1 (de)	2019-12-18	2022-10-26	Alia Therapeutics S.R.L.	Zusammensetzungen und verfahren zur behandlung von retinitis pigmentosa
EP4706689A2 (de)	2019-12-19	2026-03-11	Entrada Therapeutics, Inc.	Zusammensetzungen zur verabreichung von antisense-verbindungen
WO2021154705A1 (en)	2020-01-27	2021-08-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
AU2021220765A1 (en)	2020-02-10	2022-09-01	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing VEGF-A expression
JP7735288B2 (ja)	2020-02-18	2025-09-08	アルナイラムファーマシューティカルズ，インコーポレイテッド	アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
CN120505310A (zh)	2020-02-28	2025-08-19	Ionis制药公司	用于调节smn2的化合物和方法
GB2613225B (en)	2020-03-04	2024-01-03	Verve Therapeutics Inc	Compositions and methods for targeted RNA delivery
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
WO2021178736A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20220152270A (ko)	2020-03-06	2022-11-15	알닐람 파마슈티칼스 인코포레이티드	트랜스티레틴 (ttr)의 발현을 억제하기 위한 조성물 및 방법
WO2021188611A1 (en)	2020-03-18	2021-09-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
US20230190785A1 (en)	2020-03-30	2023-06-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
EP4127134A4 (de)	2020-04-01	2024-07-31	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen mit alpha-2a-adrenergen rezeptor (adra2a) und verfahren zur verwendung davon
AR121769A1 (es)	2020-04-06	2022-07-06	Alnylam Pharmaceuticals Inc	Composiciones y métodos para el silenciamiento de la expresión de myoc
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
EP4133076A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
CA3179678A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing scn9a expression
KR20230018377A (ko)	2020-04-27	2023-02-07	알닐람 파마슈티칼스 인코포레이티드	아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
BR112022021136A2 (pt)	2020-04-30	2022-11-29	Alnylam Pharmaceuticals Inc	Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
IL297435A (en)	2020-05-01	2022-12-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating atxn1
CN115667513A (zh)	2020-05-12	2023-01-31	田边三菱制药株式会社	用于调节Ataxin 3表达的化合物、方法和药物组合物
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
EP4150090A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
EP4150078A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231691A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
IL298406A (en)	2020-05-22	2023-01-01	Wave Life Sciences Ltd	Double stranded oligonucleotide compositions and methods relating thereto
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
EP4161552A1 (de)	2020-06-05	2023-04-12	The Broad Institute, Inc.	Zusammensetzungen und verfahren zur behandlung von neoplasien
JP2023529903A (ja)	2020-06-09	2023-07-12	アルナイラムファーマシューティカルズ，インコーポレイテッド	ＧＰＡＭ（グリセロール－３－リン酸アシルトランスフェラーゼ１、ミトコンドリア）発現をサイレンシングするためのｓｉＲＮＡ組成物および方法
EP4162050A1 (de)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
TW202214856A (zh)	2020-06-18	2022-04-16	美商阿尼拉製藥公司	黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用之方法
CN116390943A (zh)	2020-06-24	2023-07-04	维尔生物科技有限公司	工程化乙型肝炎病毒中和抗体和其用途
KR20230027235A (ko)	2020-06-25	2023-02-27	신톡스, 인크.	Il-2 콘쥬게이트 및 항-egfr 항체를 사용한 면역 종양학 병용 요법
JP7799640B2 (ja)	2020-06-29	2026-01-15	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｐｌｐ１を調節するための化合物及び方法
WO2022011262A1 (en)	2020-07-10	2022-01-13	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and compositions for treating epilepsy
US20230257745A1 (en)	2020-07-10	2023-08-17	Alnylam Pharmaceuticals, Inc.	Circular siRNAs
US12384814B2 (en)	2020-07-28	2025-08-12	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing app expression
PE20231567A1 (es)	2020-08-07	2023-10-04	Ionis Pharmaceuticals Inc	Compuestos y metodos para modular el scn2a
CN116368226A (zh)	2020-09-04	2023-06-30	维乎医疗有限公司	用于加帽rna的组合物和方法
WO2022066847A1 (en)	2020-09-24	2022-03-31	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
US20230392134A1 (en)	2020-09-30	2023-12-07	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis
WO2022076291A1 (en)	2020-10-05	2022-04-14	Alnylam Pharmaceuticals, Inc.	G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
MX2023004029A (es)	2020-10-09	2023-04-27	Synthorx Inc	Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
CA3194880A1 (en)	2020-10-09	2022-04-14	Carolina E. CAFFARO	Immuno oncology therapies with il-2 conjugates
CA3198823A1 (en)	2020-10-21	2022-04-28	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
CA3196205A1 (en)	2020-10-23	2022-04-28	Floyd E. Romesberg	Reverse transcription of polynucleotides comprising unnatural nucleotides
WO2022087329A1 (en)	2020-10-23	2022-04-28	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
IL302709A (en)	2020-11-13	2023-07-01	Alnylam Pharmaceuticals Inc	Coagulation factor iRNA compositions (F5) and methods of using them
MX2023005736A (es)	2020-11-18	2023-05-25	Ionis Pharmaceuticals Inc	Compuestos y metodos para modular la expresion de angiotensinogeno.
AU2021393417A1 (en)	2020-12-01	2023-06-29	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
EP4259795A1 (de)	2020-12-08	2023-10-18	Alnylam Pharmaceuticals, Inc.	Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3205040A1 (en)	2020-12-18	2022-06-23	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating factor xii
KR20230135585A (ko)	2020-12-23	2023-09-25	플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨	변형된 trem의 조성물 및 이의 용도
WO2022147223A2 (en)	2020-12-31	2022-07-07	Alnylam Pharmaceuticals, Inc.	2'-modified nucleoside based oligonucleotide prodrugs
AU2021411579A1 (en)	2020-12-31	2023-07-13	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4291654A2 (de)	2021-02-12	2023-12-20	Alnylam Pharmaceuticals, Inc.	Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen
WO2022174101A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Skin cancer combination therapy with il-2 conjugates and cemiplimab
WO2022174102A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
JP2024509783A (ja)	2021-02-25	2024-03-05	アルナイラムファーマシューティカルズ，インコーポレイテッド	プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
AU2022226098A1 (en)	2021-02-26	2023-08-24	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
IL305418A (en)	2021-03-04	2023-10-01	Alnylam Pharmaceuticals Inc	Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
EP4304640A1 (de)	2021-03-12	2024-01-17	Northwestern University	Antivirale impfstoffe mit kugelförmigen nukleinsäuren
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
JP2024511092A (ja)	2021-03-26	2024-03-12	ミナセラピューティクスリミテッド	ＴＭＥＭ１７３ｓａＲＮＡ組成物及び使用方法
MX2023011466A (es)	2021-03-29	2024-02-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de ácido ribonucleico de interferencia (arni) de huntingtina (htt) y métodos de uso de estas.
IL307298A (en)	2021-03-31	2023-11-01	Entrada Therapeutics Inc	Cell-penetrating circular peptides
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
WO2022226291A1 (en)	2021-04-22	2022-10-27	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating cancer
TW202309280A (zh)	2021-04-26	2023-03-01	美商艾拉倫製藥股份有限公司	跨膜絲胺酸蛋白酶６（ＴＭＰＲＳＳ６）ｉＲＮＡ組成物及其使用方法
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
JP2024518374A (ja)	2021-05-03	2024-05-01	アルナイラムファーマシューティカルズ，インコーポレイテッド	トランスサイレチン（ｔｔｒ）媒介性アミロイドーシスを治療するための組成物および方法
JP2024518476A (ja)	2021-05-10	2024-05-01	エントラーダセラピューティクス，インコーポレイティド	ｍＲＮＡスプライシングを調節するための組成物及び方法
AU2022271873A1 (en)	2021-05-10	2024-01-04	Entrada Therapeutics, Inc.	Compositions and methods for intracellular therapeutics
EP4337263A1 (de)	2021-05-10	2024-03-20	Entrada Therapeutics, Inc.	Zusammensetzungen und verfahren zur modulation der interferon-regulatorischen faktor-5 (irf-5)-aktivität
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
US20240263177A1 (en)	2021-05-20	2024-08-08	Korro Bio, Inc.	Methods and Compositions for Adar-Mediated Editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
EP4347823A1 (de)	2021-06-02	2024-04-10	Alnylam Pharmaceuticals, Inc.	Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202313679A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
TW202308663A (zh)	2021-06-04	2023-03-01	美商艾拉倫製藥股份有限公司	人類染色體９開讀框７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ劑組成物及其使用方法
EP4351541A2 (de)	2021-06-08	2024-04-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit morbus stargardt und/oder retinal-bindendem protein 4 (rbp4)
WO2022258753A1 (en)	2021-06-11	2022-12-15	Bayer Aktiengesellschaft	Type v rna programmable endonuclease systems
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
KR20240023602A (ko)	2021-06-18	2024-02-22	아이오니스 파마수티컬즈, 인코포레이티드	Ifnar1 발현을 감소시키기 위한 화합물 및 방법
WO2022271818A1 (en)	2021-06-23	2022-12-29	Entrada Therapeutics, Inc.	Antisense compounds and methods for targeting cug repeats
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
US20250034564A1 (en)	2021-06-29	2025-01-30	Korro Bio, Inc.	Methods and Compositions for ADAR-Mediated Editing
AU2022303164A1 (en)	2021-06-30	2024-01-18	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
JP2024527584A (ja)	2021-07-09	2024-07-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	ＣＮＳ送達のためのＢｉｓ－ＲＮＡｉ化合物
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
JP2024528659A (ja)	2021-07-19	2024-07-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物
CA3226887A1 (en)	2021-07-21	2023-01-26	Alnylam Pharmaceuticals, Inc.	Metabolic disorder-associated target gene irna compositions and methods of use thereof
TW202325312A (zh)	2021-07-23	2023-07-01	美商艾拉倫製藥股份有限公司	β－鏈蛋白（ＣＴＮＮＢ１）ｉＲＮＡ組成物及其使用方法
EP4377458A1 (de)	2021-07-29	2024-06-05	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa-reduktase (hmgcr)-irna-zusammensetzungen und verfahren zur verwendung davon
JP2024530647A (ja)	2021-08-03	2024-08-23	ヴァーヴ・セラピューティクス，インコーポレーテッド	標的ｒｎａ送達のための組成物および方法
CA3227852A1 (en)	2021-08-03	2023-02-09	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof
AU2022324003A1 (en)	2021-08-04	2024-02-08	Alnylam Pharmaceuticals, Inc.	iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
MX2024001573A (es)	2021-08-13	2024-02-14	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) contra el factor xii (f12) y sus metodos de uso.
JP2024538859A (ja)	2021-08-31	2024-10-24	アルナイラムファーマシューティカルズ，インコーポレイテッド	細胞死誘導ＤＦＦＡ様エフェクターＢ（ＣＩＤＥＢ）ｉＲＮＡ組成物およびその使用方法
CA3229661A1 (en)	2021-09-01	2023-03-09	Xiang Li	Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
JP2024535888A (ja)	2021-09-20	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	インヒビンサブユニットベータｅ（ｉｎｈｂｅ）モジュレーター組成物およびその使用方法
MX2024003519A (es)	2021-09-24	2024-04-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
IL311518A (en)	2021-10-01	2024-05-01	Adarx Pharmaceuticals Inc	Preparations that modulate perkalkerine and methods of using them
KR20240101590A9 (ko)	2021-10-15	2025-12-10	알닐람 파마슈티칼스 인코포레이티드	간외 전달 irna 조성물 및 이를 이용하는 방법
WO2023069603A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
JP2024541974A (ja)	2021-10-29	2024-11-13	アルナイラムファーマシューティカルズ，インコーポレイテッド	ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
CA3234636A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
US20240200078A1 (en)	2021-11-18	2024-06-20	Cornell University	Microrna-dependent mrna switches for tissue-specific mrna-based therapies
WO2023099884A1 (en)	2021-12-01	2023-06-08	Mina Therapeutics Limited	Pax6 sarna compositions and methods of use
EP4452327A1 (de)	2021-12-20	2024-10-30	Synthorx, Inc.	Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und pembrolizumab
WO2023118349A1 (en)	2021-12-21	2023-06-29	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
EP4453191A1 (de)	2021-12-23	2024-10-30	Bayer Aktiengesellschaft	Neuartige programmierbare endonukleasesysteme für kleine v-rna
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
EP4469575A2 (de)	2022-01-24	2024-12-04	Alnylam Pharmaceuticals, Inc.	Enzym-irna-wirkstoffzusammensetzungen für den heparinsulfatbiosyntheseweg und verfahren zur verwendung davon
JP2025507751A (ja)	2022-03-01	2025-03-21	クリスパー・セラピューティクス・アクチェンゲゼルシャフト	アンジオポエチン様３（ａｎｇｐｔｌ３）関連状態を処置するための方法および組成物
WO2023170435A1 (en)	2022-03-07	2023-09-14	Mina Therapeutics Limited	Il10 sarna compositions and methods of use
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
WO2023220744A2 (en)	2022-05-13	2023-11-16	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
EP4536818A1 (de)	2022-06-10	2025-04-16	Bayer Aktiengesellschaft	Neuartige programmierbare endonukleasesysteme für kleine v-rna
EP4547683A2 (de)	2022-06-30	2025-05-07	Alnylam Pharmaceuticals, Inc.	Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
EP4569113A1 (de)	2022-09-15	2025-06-18	Regeneron Pharmaceuticals, Inc.	17b-hydroxysteroiddehydrogenase-typ-13 (hsd17b13)-irna-zusammensetzungen und verfahren zu ihrer verwendung
EP4587564A2 (de)	2022-09-16	2025-07-23	Alia Therapeutics Srl	Enqp-typ-ii-cas-proteine und anwendungen davon
US12152052B2 (en)	2022-09-23	2024-11-26	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing MECP2 expression
JP2025532985A (ja)	2022-09-30	2025-10-03	アルナイラムファーマシューティカルズ，インコーポレイテッド	修飾二本鎖ｒｎａ剤
EP4619535A1 (de)	2022-11-16	2025-09-24	Alia Therapeutics Srl	Typ-ii-cas-proteine und anwendungen davon
EP4634376A2 (de)	2022-12-13	2025-10-22	Bayer Aktiengesellschaft	Gentechnisch hergestellte typ-v-rna-programmierbare endonukleasen und deren verwendungen
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024134199A1 (en)	2022-12-22	2024-06-27	Mina Therapeutics Limited	Chemically modified sarna compositions and methods of use
JP2026502531A (ja)	2023-01-11	2026-01-23	アリアセラピューティクスエスアールエル	Ｉｉ型ｃａｓタンパク質およびその適用
EP4662311A2 (de)	2023-02-09	2025-12-17	Alnylam Pharmaceuticals, Inc.	Reversirmoleküle und verfahren zu ihrer verwendung
EP4665865A1 (de)	2023-02-17	2025-12-24	Anjarium Biosciences AG	Verfahren zur herstellung von dna-molekülen und zusammensetzungen und verwendungen davon
WO2024196937A1 (en)	2023-03-20	2024-09-26	Synthorx, Inc.	Cancer therapy with il-2 peg conjugates
WO2024216155A1 (en)	2023-04-12	2024-10-17	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery of double-stranded rna agents
EP4698652A2 (de)	2023-04-20	2026-02-25	Adarx Pharmaceuticals, Inc.	Mapt-modulierende zusammensetzungen und verfahren zur verwendung davon
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
WO2024226499A1 (en)	2023-04-24	2024-10-31	The Broad Institute, Inc.	Compositions and methods for modifying fertility
EP4709855A2 (de)	2023-05-12	2026-03-18	Alnylam Pharmaceuticals, Inc.	Einzelsträngige schleifenoligonukleotide
KR20260021635A (ko)	2023-05-12	2026-02-13	아다르엑스 파마슈티컬스, 인크.	Nmda 리간드 접합 화합물 및 이의 용도
CN121335980A (zh)	2023-05-26	2026-01-13	阿达尔克斯制药有限公司	Sod1调节组合物及其使用方法
TW202506137A (zh)	2023-06-20	2025-02-16	美商雅迪克斯製藥公司	Ｌｒｒｋ２調節組合物及其使用方法
WO2025003344A1 (en)	2023-06-28	2025-01-02	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025015338A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
AU2024299328A1 (en)	2023-07-21	2026-01-22	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025034422A1 (en)	2023-08-04	2025-02-13	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating ctnnb1-associated disorders
WO2025064660A2 (en)	2023-09-21	2025-03-27	Alnylam Pharmaceuticals, Inc.	Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
WO2025072699A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Aminoglycosides for delivery of agents to the kidney
WO2025072713A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Polymyxins for delivery of agents to the kidney
WO2025072672A2 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Slc6a19-targeting modulatory nucleic acid agents
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
TW202521691A (zh)	2023-10-06	2025-06-01	美商藍岩醫療公司	經工程化之v型rna可程式核酸內切酶及其用途
AU2024369609A1 (en)	2023-10-31	2025-12-11	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
TW202543656A (zh)	2024-02-19	2025-11-16	美商旗艦先鋒創新有限責任（Ｖｉｉ）公司	靶向ＣＩＤＥＢ之ＲＮＡｉ藥劑及相關方法
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en)	2024-03-25	2025-10-02	Synthorx, Inc.	Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
WO2025210147A1 (en)	2024-04-04	2025-10-09	Alia Therapeutics Srl	Type v cas proteins and applications thereof
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026027887A2 (en)	2024-08-02	2026-02-05	Mina Therapeutics Limited	Hbg1/2-sarna compositions and methods of use
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4470954A (en) *	1983-06-13	1984-09-11	Chiknas Steven G	Rotor or carrier for centrifugal analyzer and bead washer
DD238395A1 (de) *	1985-06-19	1986-08-20	Akad Wissenschaften Ddr	Verfahren zur selektiven fixierung von biologisch aktiven stoffen
US4806546A (en) *	1985-09-30	1989-02-21	Miles Inc.	Immobilization of nucleic acids on derivatized nylon supports
JPS62197425A (ja) *	1986-02-25	1987-09-01	Toyo Soda Mfg Co Ltd	球状熱可塑性樹脂の製造方法
GB2197720A (en) *	1986-11-20	1988-05-25	Nat Res Dev	Immobilisation of polynucleotides
WO1988006189A1 (en) *	1987-02-12	1988-08-25	Sdi Diagnostics, Inc.	Test system, test device and method for detecting pathogenic organisms and antibiotic resistance genes in body fluids
IL85551A0 (en) *	1987-04-01	1988-08-31	Miles Inc	Rapid hybridization assay and reagent system used therein
US4921805A (en) *	1987-07-29	1990-05-01	Life Technologies, Inc.	Nucleic acid capture method
US4921788A (en) *	1988-04-12	1990-05-01	The Research Foundation Of State University Of New York	Competitive nucleic acid immunoassay for the detection of analytes
IE904365A1 (en) *	1990-02-13	1991-08-14	Epitope	Stick probe device for detection of antibodies

1990
- 1990-09-04 DE DE69032425T patent/DE69032425T2/de not_active Expired - Lifetime
- 1990-09-04 DK DK90309671T patent/DK0455905T3/da active
- 1990-09-04 EP EP96113623A patent/EP0745689A3/de not_active Withdrawn
- 1990-09-04 ES ES90309671T patent/ES2116977T3/es not_active Expired - Lifetime
- 1990-09-04 EP EP90309671A patent/EP0455905B1/de not_active Expired - Lifetime
- 1990-09-04 AT AT90309671T patent/ATE167523T1/de not_active IP Right Cessation
- 1990-09-17 JP JP2244155A patent/JPH0420300A/ja active Pending
1994
- 1994-10-28 US US08/331,296 patent/US5514785A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH0420300A (ja)	1992-01-23
EP0455905A2 (de)	1991-11-13
ATE167523T1 (de)	1998-07-15
DE69032425T2 (de)	1998-11-26
EP0455905B1 (de)	1998-06-17
DK0455905T3 (da)	1998-12-07
US5514785A (en)	1996-05-07
EP0745689A3 (de)	1996-12-11
ES2116977T3 (es)	1998-08-01
EP0455905A3 (en)	1992-10-07
EP0745689A2 (de)	1996-12-04

Legal Events

Date	Code	Title	Description
1999-07-15	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE69032425D1 (de)	1998-07-23	Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden
DE69509925D1 (de)	1999-07-01	Verfahren und vorrichtung zur herstellung von mikromatrizen für biologische proben
ATE147860T1 (de)	1997-02-15	Verfahren zur immobilisierung von nukleinsäure an einer festen oberfläche zur anwendung in nukleinsäure-hybridizierungstests
DE69535240D1 (de)	2006-11-09	Zusammensetzungen und Verfahren für die gleichzeitige Detektion und Quantifizierung von einer Mehrheit spezifischer Nuklein Säure Sequenzen
PT975427E (pt)	2001-08-30	Dispositivo que permite um ensaio utilizacao de uma mebrana para fabricar o referido dispositivo e metodo para a deteccao de um analito utilizando tal dispositivo
ATE220341T1 (de)	2002-07-15	Verfahren zur trennung doppelsträngiger dna von einzelsträngiger dna oder rna
ATE138197T1 (de)	1996-06-15	Analyseelement und verfahren zu seiner herstellung
EP0684952A4 (de)	1996-12-27	Verfahren zur immobilisierung von nukleinsäure-molekülen.
ATE175722T1 (de)	1999-01-15	Verfahren zur charakterisierung genomischer dna
CA2250706A1 (en)	1997-11-06	Method and reagent for detecting multiple nucleic acid sequences in a test sample
DE69706187D1 (de)	2001-09-20	Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
DE69206080D1 (de)	1995-12-21	Element und verfahren für nuklein-säure amplifikation und nachweis unter verwendung von adhärierten sonden.
DE69404657D1 (de)	1997-09-04	Verfahren und vorrichtung zur durchfürung einer vielzahl von chemischen reaktionen auf einer traegerflaeche
ATE91708T1 (de)	1993-08-15	Verfahren zur freisetzung von rns und dns aus zellen.
ATE110851T1 (de)	1994-09-15	Testträger für die analyse einer probenflüssigkeit und verfahren zu seiner herstellung.
DE3786388D1 (de)	1993-08-05	Analytisches geraet und verfahren zum nachweis von chlamydia trachomatis und neisseria gonorrhoeae.
ATE334224T1 (de)	2006-08-15	Nukleinsäure-sonden für chlamydia pneumoniae
DE69026024D1 (de)	1996-04-25	Künstlicher Träger zur Immobilisierung von biologischen Proteinen und Verfahren zu seiner Herstellung
ATE194390T1 (de)	2000-07-15	Nukleinsäuresonden für mykobacterium tuberkulosis
DE59307931D1 (de)	1998-02-12	Spezifische Gensonden und Verfahren zur Diagnostik von Candida albicans
DE59812354D1 (de)	2005-01-13	Analytisches Messverfahren und seine Verwendung
DE59007814D1 (de)	1995-01-12	Neisseria gonorrhoeae-spezifische Oligonuleotid-Sonden.
FR2616682B1 (fr)	1989-10-06	Appareil d'agitation selective des teintes de base de peinture, notamment pour carrosseries automobiles
WO1996019587A3 (en)	1996-09-19	Methods of immobilizing oligonucleotides to solid support materials and methods of using support bound oligonucleotides
CA2099543A1 (en)	1994-01-08	Photochemical labelling of nucleic acids with digoxigenin reagents and their use in gene probe test systems